<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0509211009
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KIVEXA film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ABACAVIR,LAMIVUDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600,300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1676.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Pozna&#x144; Sp&#xF3;&#x142;ka Akcyjna" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Poznań Spółka Akcyjna
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Kivexa is used to treat HIV (human immunodeficiency virus) infection in adults, adolescents and in children weighing at least 25 kg. </strong></p><p>Kivexa contains two active ingredients that are used to treat HIV infection: abacavir and lamivudine.&nbsp; These belong to a group of anti-retroviral medicines called <em>nucleoside analogue reverse transcriptase inhibitors (NRTIs)</em>.</p><p>Kivexa does not completely cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with Kivexa in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Kivexa:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> <em>(hypersensitive)</em> to abacavir (or any other medicine containing abacavir &mdash; (e.g. <strong>Trizivir, Triumeq</strong> or <strong>Ziagen</strong>), lamivudine or any of the other ingredients of this medicine (listed in Section 6)</p><p>&Uacute; <strong>Carefully read all the information about hypersensitivity reactions in Section 4</strong>.</p><p><strong>Check with your doctor</strong> if you think this applies to you. <strong>Do not take Kivexa</strong></p><p><strong>Take special care with Kivexa</strong></p><p>Some people taking Kivexa or other combination treatments for HIV are more at risk of serious side effects. You need to be aware of the extra risks:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you<strong> </strong>have<strong> moderate or severe liver disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>liver disease,</strong> including hepatitis B or C (if you have hepatitis B infection, do not stop Kivexa without your doctor&rsquo;s advice, as your hepatitis may come back)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are seriously<strong> overweight</strong> (especially if you are a woman)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you<strong> </strong>have<strong> a kidney problem </strong></p><p>&Uacute; <strong>Talk to your doctor if any of these apply to you before using Kivexa.</strong> You may need extra check-ups, including blood tests, while you are taking your medicine. <strong>See Section 4 for more information. </strong></p><p><u>Abacavir hypersensitivity reactions</u></p><p>Even patients who don&rsquo;t have the HLA-B*5701 gene may still develop a <strong>hypersensitivity reaction</strong> (a serious allergic reaction)</p><p>&Uacute; <strong>Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.</strong></p><p><strong>Risk of heart attack</strong></p><p>It cannot be excluded that abacavir may increase the risk of having a heart attack.</p><p>&Uacute; <strong>Tell your doctor </strong>if you have heart problems, if you smoke, or have other illnesses that may increase your risk of heart disease such as high blood pressure, or diabetes. Do not stop taking Kivexa unless your doctor advises you to do so.</p><p><strong>Look out for important symptoms</strong></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you are taking Kivexa.</p><p>&Uacute; <strong>Read the information &lsquo;Other possible side effects of combination therapy for HIV&rsquo; in Section&nbsp;4 of this leaflet</strong>.</p><p><strong>Other medicines and Kivexa</strong></p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines</strong>, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.</p><p>Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Kivexa.</p><p>&nbsp;</p><p><strong>These medicines should not be used with Kivexa:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emtricitabine, to treat <strong>HIV infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicinal products containing lamivudine, used to treat <strong>HIV infection</strong> or <strong>hepatitis B infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high doses of <strong>trimethoprim/sulfamethoxazole</strong>, an antibiotic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cladribine, used to treat <strong>hairy cell leukaemia</strong></p><p>&Uacute; <strong>Tell your doctor</strong> if you are being treated with any of these.</p><p><strong>Some medicines interact with Kivexa</strong></p><p>These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>phenytoin</strong>, for treating <strong>epilepsy</strong>.<strong>&nbsp; </strong></p><p>&Uacute; <strong>Tell your doctor</strong> if you are taking phenytoin. Your doctor may need to monitor you while you are taking Kivexa.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>methadone</strong>,<strong> </strong>used as a <strong>heroin substitute</strong>.<strong> </strong>Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be&nbsp;changed.</p><p>&Uacute; <strong>Tell your doctor</strong> if you are taking methadone.</p><p>&middot;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing <strong>sorbitol and other</strong> <strong>sugar alcohols</strong> (such as xylitol, mannitol, lactitol or maltitol), if taken regularly.</p><p>&Uacute;&nbsp; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Riociguat,</strong> for treating <strong>high blood pressure in the blood vessels</strong> (the pulmonary arteries) that carry blood from the heart to the lungs. Your doctor may need to reduce your riociguat dose, as abacavir may increase riociguat blood levels.&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p><strong>Kivexa is not recommended for use during pregnancy</strong>. Kivexa and similar medicines may cause side effects in unborn babies.</p><p>If you have taken Kivexa during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.<!--[if supportFields]><span
style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0a7fd643-66db-4c00-83c0-fa6cb757370c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Breast-feeding</strong></p><p>Breast-feeding <strong>is not recommended<em> </em></strong>in<strong> </strong>women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Kivexa can also pass into your breast milk.</p><p>If you are breast-feeding, or thinking about breast-feeding, you <strong>should discuss it with your doctor as soon as possible.</strong></p><p><strong>Driving and using machines</strong></p><p>Kivexa<strong> </strong>may cause side effects which could affect your ability to drive or use machines.</p><p><strong>Talk to your doctor </strong>about your ability to drive or operate machines while taking Kivexa.</p><p><strong>&nbsp;</strong></p><p><strong>Important information about some of the other ingredients of Kivexa tablets</strong></p><p>Kivexa contains a colouring called sunset yellow (E110), this may cause allergic reactions in some people.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor has told you</strong>. Check with your doctor or pharmacist if you are not sure.</p><p><strong>The recommended dose of Kivexa for adults, adolescents and children weighing 25 kg or more is one tablet once a day</strong>.</p><p>Swallow the tablets whole, with some water. Kivexa can be taken with or without food.</p><p><strong>Stay in regular contact with your doctor</strong></p><p>Kivexa helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.</p><p><strong>Keep in touch with your doctor, and do not stop taking Kivexa </strong>without your doctor&rsquo;s advice.</p><p><strong>If you take more Kivexa than you should</strong></p><p>If you accidentally take too much Kivexa, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice.</p><p><strong>If you forget to take Kivexa</strong></p><p>If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>It is important to take Kivexa regularly, because if you take it at irregular intervals, you may be more likely to have a hypersensitivity reaction.</p><p><strong>If you have stopped taking Kivexa</strong></p><p>If you have stopped taking Kivexa for any reason &mdash; especially because you think you are having side effects, or because you have other illness:</p><p><strong>Talk to your doctor before you start taking it again</strong>. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been related, <strong>you will be told never again to take Kivexa, or any other medicine containing abacavir (e.g. Trizivir, Triumeq or Ziagen)</strong>. It is important that you follow this advice.</p><p>If your doctor advises that you can start taking Kivexa again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>Like all medicines, this medicine can cause side effects, although not everyone gets them.</p><p>When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Kivexa or other medicines you are taking, or an effect of the HIV disease itself. <strong>So it is very important to talk to your doctor about any changes in your health</strong>.</p><p>Even patients who don&rsquo;t have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction), described in this leaflet in the panel headed &lsquo;Hypersensitivity reactions&rsquo;.</p><p><strong>It is very important that you read and understand the information about this serious reaction</strong>.</p><p><strong>As well as the side effects listed below for Kivexa</strong>, other conditions can develop during combination therapy for&nbsp;HIV.</p><p>It is important to read the information later in this section under &lsquo;Other possible side effects of combination therapy for&nbsp;HIV&rsquo;.</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>Hypersensitivity reactions</strong></p><p><strong>Kivexa</strong> contains <strong>abacavir</strong> (which is also an active substance in medicines such as <strong>Trizivir,</strong> <strong>Triumeq</strong> and <strong>Ziagen</strong>). Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction.&nbsp;&nbsp; These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.<strong> </strong></p><p><strong>Who gets these reactions?</strong></p><p>Anyone taking Kivexa could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Kivexa.</p><p>You are more likely to develop this reaction if you have a gene called <strong>HLA-B*5701</strong> (but you can get a reaction even if you do not have this gene). You should have been tested for this gene before Kivexa was prescribed for you. <strong>If you know you have this gene, tell your doctor before you take Kivexa.</strong></p><p>About 3 to 4 in every 100 patients treated with abacavir in a clinical trial who did not have the HLA-B*5701 gene developed a hypersensitivity reaction.</p><p><strong>What are the symptoms?</strong></p><p>The most common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>fever</strong> (high temperature) and <strong>skin rash</strong>.</p><p>Other common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness.</p><p>Other symptoms include:</p><p>Pains in the joints or muscles, swelling of the neck, shortness of breath, sore throat, cough, occasional headaches, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.</p><p><strong>When do these reactions happen?</strong></p><p>Hypersensitivity reactions can start at any time during treatment with Kivexa but are more likely during the first 6 weeks of treatment.</p><p><strong>Contact your doctor immediately:</strong></p><p><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get a skin rash, OR</strong></p><p><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get symptoms from at least 2 of the following</strong> <strong>groups:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - fever</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - shortness of breath, sore throat or cough</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - nausea or vomiting, diarrhoea or abdominal pain</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - severe tiredness or achiness, or generally feeling ill.</p><p><strong>Your doctor may advise you to stop taking Kivexa.</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>If you have stopped taking Kivexa</strong></p><p>If you have stopped taking Kivexa because of a hypersensitivity reaction,<strong> you must NEVER AGAIN take Kivexa, or any other medicine containing abacavir (e.g., Trizivir, Triumeq or Ziagen)</strong>. If you do, within hours, your blood pressure could fall dangerously low, which could result in death.</p><p>If you have stopped taking Kivexa for any reason &mdash; especially because you think you are having side effects, or because you have other illness:</p><p><strong>Talk to your doctor before you start again</strong>. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been, <strong>you will then be told never again to take Kivexa, or any other medicine containing abacavir (e.g., Trizivir, Triumeq or Ziagen)</strong>. It is important that you follow this advice.</p><p>Occasionally hypersensitivity reactions have developed in people who start taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.</p><p>Very rarely patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have developed a hypersensitivity reaction when they start taking these medicines again.</p><p>If your doctor advises that you can start taking Kivexa again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p><p><strong>If you are hypersensitive to Kivexa, return all your unused Kivexa tablets for safe disposal.</strong> Ask your doctor or pharmacist for advice.</p><p>The Kivexa pack includes an <strong>Alert Card</strong>, to remind you and medical staff about hypersensitivity reactions. <strong>Detach this card and keep it with you at all times</strong>.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect<strong> up to 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick <em>(vomiting)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick <em>(nausea)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, lack of energy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (high temperature)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general feeling of being unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping <em>(insomnia)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain and discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritated or runny nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect<strong> up to 1 in 100</strong> people and may show up in blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a low red blood cell count <em>(anaemia)</em> or low white blood cell count <em>(neutropenia)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the level of liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in the number of cells involved in blood clotting (<em>thrombocytopenia</em>).</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation <em>(hepatitis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas <em>(pancreatitis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue.</p><p>Rare side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in an enzyme called <em>amylase.</em></p><p><strong>&nbsp;</strong></p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingly feelings in the skin (pins and needles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of weakness in the limbs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) <em>(erythema multiforme)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals<em> (Stevens&ndash;Johnson syndrome)</em>, and a more severe form causing skin peeling in more than 30% of the body surface <em>(toxic epidermal necrolysis)</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (excess lactic acid in the blood)</p><p>&Uacute; <strong>If you notice any of these symptoms contact a doctor urgently</strong>.</p><p>Very rare side effects that may show up in blood tests are:<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a failure of the bone marrow to produce new red blood cells (<em>pure red cell aplasia</em>).</p><p>&nbsp;</p><p><strong>If you get side effects</strong></p><p>&Uacute; <strong>Tell your doctor or pharmacist</strong> if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Other possible side effects of combination therapy for HIV</strong></p><p>Combination therapy such as Kivexa may cause other conditions to develop during HIV treatment.</p><p><strong>Symptoms of infection and inflammation</strong></p><p><strong>Old infections may flare up</strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (<em>opportunistic infections</em>). Such infections may have been &ldquo;silent&rdquo; and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include <strong>fever</strong>, plus some of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (<em>autoimmune disorders</em>).&nbsp; The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (rapid or irregular heartbeat) or tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity (excessive restlessness and movement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body</p><p><strong>If you get any symptoms of infection</strong> and inflammation or if you notice any of the symptoms above:</p><p>&Uacute; <strong>Tell your doctor immediately</strong>. Do not take other medicines for the infection without your doctor&rsquo;s advice.</p><p><strong>You may have problems with your bones</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they drink alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if their immune systems are very weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are overweight.</p><p><strong>Signs of osteonecrosis include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty moving.</p><p>If you notice any of these symptoms: <strong>Tell your doctor</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not take this medicine after the expiry date shown on the carton. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p style="text-align:center"><strong>ALERT CARD</strong></p><p style="text-align:center"><strong>MANDATORY PACKAGING INFORMATION</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>IMPORTANT - ALERT CARD</strong></p><p style="text-align:center"><strong><em>KIVEXA </em>(abacavir Sulfate/Lamivudine) Tablets</strong></p><p style="text-align:center"><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><p>Since <em>KIVEXA </em>contains abacavir, some patients taking <em>KIVEXA </em>may develop a hypersensitivity reaction (serious allergic reaction) which <strong>can be life-threatening </strong>if treatment with <em>KIVEXA </em>is continued. <strong>CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking <em>KIVEXA </em>if: </strong></p><p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get a skin rash OR</p><p>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get one or more symptoms from at least TWO of the following groups:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, sore throat, or cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomiting or diarrhoea or abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe tiredness or achiness or generally ill feeling.</p><p>If you have discontinued <em>KIVEXA </em>due to this reaction, <strong>YOU MUST NEVER TAKE </strong><em>KIVEXA</em>, or any other medicine containing abacavir (<em>ZIAGEN, TRIZIVIR </em>or <em>TRIUMEQ</em>) again as <strong>within hours </strong>you may experience a life-threatening lowering of your blood pressure or death.</p><p><strong>CARTON PANEL </strong></p><p>The following text must be included on one of the carton panels.</p><p><strong>The Alert Card enclosed contains important safety information </strong></p><p>WARNING! In case of any symptoms suggesting hypersensitivity reactions, contact your doctor IMMEDIATELY.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances in each Kivexa film-coated tablet are 600 mg of abacavir (as sulfate) and 300 mg of lamivudine.</p><p><strong>The other ingredients are: </strong></p><p><u>Core:</u></p><p>Magnesium stearate, Microcrystalline cellulose, Sodium starch glycollate.</p><p><u>Coating</u>:</p><p>Opadry Orange YS-1-13065-A containing:</p><p>Hypromellose (E464), Titanium dioxide (E171), Macrogol 400, Polysorbate 80 (E433), Sunset yellow aluminium lake (E110).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Kivexa film-coated tablets are engraved with ‘GS FC2’ on one side. They are orange and capsule-shaped and are provided in blister packs containing 30 tablets.

KIVEXA is a trademark owned by or licensed to the ViiV Healthcare group of companies. 
© 2024 ViiV Healthcare group of companies. All rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Packed by:</strong></p><p>Glaxo Wellcome S.A.*, Aranda, Spain</p><p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>*member of GSK group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number:  UK_Issue 31 Draft 1
This leaflet was last revised on: 10 January 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يستخدم كيـﭭـيكسا في علاج عدوى الإيدز (فيروس نقص المناعة البشري) لدى البالغين والمراهقين، والأطفال الذين لا يقل وزنهم عن </strong><strong>25</strong><strong> كيلوجرامًا. </strong></p><p dir="RTL">يحتوي كيـﭭـيكسا على مادتين فعالتين تُستخدمان في علاج عدوى الإيدز (فيروس نقص المناعة البشري)، وهما: أباكاﭬـير، ولاميـﭭـودين. تنتمي المادتان إلى فئة من الأدوية المضادة للفيروسات الرجعية تُسمى <em>الأدوية النيوكليوزيدية المضادة لأنزيم المنتسخة المعاكس</em> <em>(NRTI)</em>.</p><p dir="RTL">لا يقضي كيـﭭـيكسا على عدوى الإيدز (فيروس نقص المناعة البشري) بشكل كامل، وإنما يقلل من انتشار الفيروس في الجسم ويبقيه في مستويات منخفضة. كما يعمل على زيادة عدد خلايا CD4 في الدم. وخلايا CD4 هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">وتختلف استجابات المرضى للعلاج بكيـﭭـيكسا. سوف يراقب الطبيب مدى فاعلية العلاج لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول كيـﭭـيكسا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية</strong> <em>(فرط حساسية)</em> من أباكاﭬـير (أو أي دواء آخر يحتوي على أباكاﭬـير &mdash; (على سبيل المثال: <strong>تريزيڤير</strong> أو <strong>ترايوميك</strong> أو <strong>زياجين</strong>)، أو لاميـﭭـودين أو أي مكوّنات أخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL"><strong>&szlig;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم </strong><strong>4</strong><strong>.</strong></p><p dir="RTL"><strong>راجع الطبيب</strong> إذا كنت تعتقد أن هذه الحالة تنطبق عليك. <strong>لا تتناول كيـﭭـيكسا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي توخي الحذر عند استخدام كيـﭭـيكسا</strong></p><p dir="RTL">بعض المرضى الذين يتناولون كيـﭭـيكسا أو غيره من العلاجات المركبة لفيروس نقص المناعة البشري يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة. يجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>مصابًا بمرض متوسط أو حاد في الكبد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت سابقًا <strong>بمرض في الكبد</strong>، بما في ذلك إلتهاب الكبد الوبائي (ب) أو (ج) (إذا كنت مصابًا بعدوى إلتهاب الكبد الوبائي (ب)، فلا تتوقف عن تناول كيـﭭـيكسا بدون إستشارة الطبيب، إذ قد يعاودك إلتهاب الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>البدانة المفرطة</strong> (على الأخص إذا كنتِ امرأة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>مشكلة في الكلى</strong></p><p dir="RTL"><strong>&szlig;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استشر طبيبك إذا كنت تعاني من أي من الأمراض السالفة قبل تناول كيـﭭـيكسا.</strong> قد تحتاج إلى إجراء المزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناولك العلاج. <strong>راجع القسم </strong><strong>4</strong><strong> لمزيد من المعلومات. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاعلات فرط الحساسية من أباكاﭬـير</u></p><p dir="RTL">حتى المرضى الذين لا يوجد لديهم جين HLA-B*5701، قد يصابون <strong>بتفاعل فرط الحساسية</strong> (تفاعل تحسسي خطير)</p><p dir="RTL"><strong>&szlig;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم </strong><strong>4</strong><strong> من هذه النشرة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>خطر التعرض للإصابة بأمراض القلب والأوعية الدموية</strong><strong> </strong>لا يمكن استبعاد أن أباكاﭬـير قد يزيد من خطر الإصابة بأمراض القلب والأوعية الدموية .</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك </strong>إذا كنت تعاني من مشكلات في القلب والأوعية الدموية أو كنت تدخن أو تعاني من أي أمراض أخرى قد يزيد من خطر الإصابة بأمراض القلب والأوعية الدموية ، مثل إرتفاع ضغط الدم أو مرض السكري.</p><p dir="RTL">لا تتوقف عن تناول كيـﭭـيكسا ما لم ينصحك الطبيب بالتوقف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض مهمة يجب الإنتباه لها</strong></p><p dir="RTL">قد تتطور لدى بعض الأشخاص الذين يتناولون أدوية لعلاج &rlm;‫عدوى الإيدز (فيروس نقص المناعة البشري) بعض الحالات الأخرى التي قد تكون خطيرة. يجب عليك معرفة العلامات والأعراض المهمة التي يجب الحذر منها أثناء تناول كيـﭭـيكسا.</p><p dir="RTL"><strong>&szlig;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اقرأ المعلومات الموجودة في &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري&quot; في القسم </strong><strong>4</strong><strong> من هذه النشرة.</strong></p><p dir="RTL"><strong>الأدوية الأخرى وكيـﭭـيكسا</strong></p><p dir="RTL"><strong>قم بإبلاغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى،</strong> أو تناولت أي أدوية مؤخرًا، بما في ذلك الأدوية التي تحتوي على أعشاب، أو الأدوية الآخرى التي يمكن شراؤها بدون وصفة طبية.</p><p dir="RTL">تذكر إبلاغ الطبيب أو الصيدلي إذا كنت تبدأ في تناول دواء جديد أثناء تناولك لكيـﭭـيكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا يمكن تناول الأدوية التالية مع كيـﭭـيكسا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمتريسيتابين، لعلاج <strong>عدوى الإيدز (فيروس نقص المناعة البشري)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتجات الدوائية الأخرى التي تحتوي على لاميـﭭـودين، المستخدم في علاج <strong>عدوى الإيدز (فيروس نقص المناعة البشري) أو عدوى إلتهاب الكبد الوبائي (ب)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعات كبيرة من <strong>ترايميثوبريم/سلفاميثوكسازول</strong>، مضاد حيوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلادريبين، المستخدم في علاج <strong>خلايا سرطان الدم المشعرة</strong></p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك</strong> إذا كنت تُعالج بأي من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعل بعض الأدوية مع كيـﭭـيكسا</strong></p><p dir="RTL">ويشمل ذلك ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فينيتوين،</strong> لعلاج <strong>الصرع</strong>.&nbsp;</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك</strong> إذا كنت تتناول فينيتوين. قد يحتاج الطبيب إلى مراقبة حالتك طوال فترة تناول كيـﭭـيكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ميثادون،</strong> المستخدم بمثابة <strong>بديل للهيروين</strong>. يزيد أباكاﭬـير من معدل تخلص الجسم من ميثادون. إذا كنت تتناول ميثادون، فسيتم فحصك لعلاج أي أعراض انسحاب. قد ينبغي تعديل جرعة ميثادون الخاصة بك.</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك</strong> إذا كنت تتناول ميثادون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي الأدوية عادة السائلة منها على <strong>محلي</strong> <strong>سوربيتول</strong> <strong>وكحول محلاه أخرى </strong>(كا زيليتول ومانيتول واللاكتول والمالتيتول)، ما إذا استخدمت بشكل منتظم.</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك او الصيدلي</strong> إذا كنت تتناول اي منها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريوسيجوات</strong> والذي يستخدم <strong>لعلاج ارتفاع ضغط الدم</strong> <strong>في الأوعية الدموية</strong> (الشرايين الرئوية)، التي تنقل الدم من القلب إلى الرئتين، قد يحتاج الطبيب المعالج إلى تقليل جرعة ريوسيجوات الخاصة بك، لأن دواء أباكاڤير يزيد من مستويات دواء ريوسيجوات في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL"><strong>لا يُوصى بتناول كيـﭭـيكسا أثناء فترة الحمل.</strong> ربما يتسبب كيـﭭـيكسا والأدوية المماثلة في حدوث آثار جانبية للأجنة.</p><p dir="RTL">إذا كنتِ قد تناولتِ كيـﭭـيكسا أثناء حملكِ، فقد يطلب طبيبكِ إجراء فحوصات دم دورية وغيرها من الفحوصات التشخيصية لمراقبة نمو طفلكِ. عند الأطفال الذين تناولت أمهاتهم الأدوية النيوكليوزيدية المضادة لأنزيم المنتسخة المعاكس (NRTI) أثناء الحمل، نجد أن الفائدة من الوقاية ضد فيروس نقص المناعة البشري فاقت خطر الإصابة بآثار جانبية.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;color:black'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;color:black'>VAULT_ND_c1fe7ad4-f929-4d9e-a6ae-720ecfc28f41
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;color:black'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;<strong>لا ينصح </strong>بالرضاعة الطبيعية للنساء المتعايشات مع فيروس نقص المناعة البشرية ، لأن عدوى فيروس نقص المناعة البشري يمكنها الانتقال إلى الطفل عبر لبن الأم. يمكن أيضًا أن تنتقل كمية بسيطة من مكونات كيـﭭـيكسا إلى الطفل عبر لبن الأم.</p><p dir="RTL">إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تفكرين في ذلك<strong>:</strong><strong> </strong><strong>يجب عليك مناقشة الأمر مع طبيبك في أقرب وقت ممكن</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يُسبب كيـﭭـيكسا آثارًا جانبية قد تؤثر على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>راجع طبيبك</strong> بشأن قدرتك على القيادة أو تشغيل الآلات أثناء تناول كيـﭭـيكسا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات مهمة عن بعض المكونات الأخرى في أقراص كيـﭭـيكسا</strong></p><p dir="RTL">يحتوي كيـﭭـيكسا على مادة ملونة يُطلق عليها أصفر لون غروب الشمس (E110)، الذي قد يسبب تفاعلات تحسسية لدى بعض الأشخاص.</p><p dir="RTL">يحتوي هذا الدواء على أقل من واحد ملي مول من الصوديوم (23 ملجم) لكل قرص، مما يعني أنه في الأساس &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب دائمًا الالتزام بتعليمات الطبيب بدقة فيما يتعلق بطريقة تناول هذا الدواء.</strong> راجع الطبيب أو الصيدلي لديك في حالة عدم التأكد بشأن طريقة الاستعمال.</p><p dir="RTL"><strong>الجرعة المُوصى بها من كيـﭭـيكسا للبالغين والمراهقين والأطفال الذين تبلغ أوزانهم </strong><strong>25</strong><strong> كيلوجرامًا فأكثر هي قرص واحد في اليوم. </strong></p><p dir="RTL">ابتلع الأقراص كاملة، مع شرب بعض من الماء. يمكن تناول كيـﭭـيكسا مع الطعام أو بدونه.</p><p dir="RTL"><strong>تواصل بانتظام مع طبيبك</strong></p><p dir="RTL">يساعد كيـﭭـيكسا في التحكم في حالتك الصحية. ويجب عليك تناوله يوميًا لمنع تفاقم المرض. قد تصاب بعدوى وأمراض أخرى ترتبط بعدوى الإيدز (فيروس نقص المناعة البشري).</p><p dir="RTL"><strong>حافظ على التواصل مع طبيبك، ولا تتوقف عن تناول كيـﭭـيكسا </strong>بدون استشارته أولاً.</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من كيـﭭـيكسا عما ينبغي تناوله</strong></p><p dir="RTL">في حالة تناول جرعة زائدة من كيـﭭـيكسا دون قصد، اتصل بالطبيب أو الصيدلي، أو توجه إلى قسم الطوارئ بأقرب مستشفى للحصول على الإستشارة الإضافية.</p><p dir="RTL"><strong>في حالة نسيان تناول كيـﭭـيكسا</strong></p><p dir="RTL">في حالة نسيان تناول الجرعة، يجب تناولها فور تذكرها. ثم أكمل العلاج كما في السابق.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك.</p><p dir="RTL">من المهم تناول كيـﭭـيكسا بإنتظام، لأنك إذا كنت تتناوله على فترات غير منتظمة، فقد تصبح أكثر عُرضة للإصابة بتفاعل فرط الحساسية.</p><p dir="RTL"><strong>في حالة التوقف عن تناول كيـﭭـيكسا</strong></p><p dir="RTL">في حال التوقف عن تناول كيـﭭـيكسا لأي سبب من الأسباب، خاصة إذا كنت تعتقد أنك تعاني من بعض الأعراض الجانبية أو أنك مُصاب بأي مرض آخر:</p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استئناف تناول الدواء مرة أخرى.</strong> سوف يتحقق الطبيب من علاقة هذه الأعراض بتفاعل فرط الحساسية. إذا رأى الطبيب أن هذه الأعراض قد تكون مرتبطة بتفاعل فرط الحساسية، <strong>فسوف يُطلب منك عدم تناول كيـﭭـيكسا مرة أخرى أو أي دواء آخر يحتوي على أباكاﭬـير (على سبيل المثال: تريزيڤير، أو ترايوميك، أو زياجين).</strong> من المهم الالتزام بهذه النصيحة.</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول كيـﭭـيكسا مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على الرعاية الطبية إن لزم الأمر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أثناء علاج فيروس نقص المناعة البشري، قد تحدث زيادة في الوزن وفي مستويات الدهون والجلوكوز في الدم. يتعلق ذلك - بشكل جزئي - باستعادة الصحة وأسلوب الحياة، أما في حالة زيادة الدهون في الدم، فيعود السبب في زيادتها في بعض الأحيان إلى أدوية فيروس نقص المناعة البشري نفسها. سوف يفحص الطبيب هذه التغيرات.</p><p dir="RTL">مثله مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، لكن ليس بالضرورة أن يصاب بها جميع الأشخاص.</p><p dir="RTL">أثناء العلاج من فيروس نقص المناعة البشري، قد يصعب تحديد ما إذا كان أي عرض يطرأ هو أثر جانبي لتناول دواء كيـﭭـيكسا أو أي أدوية أخرى تتناولها، أم أثر طبيعي للمرض ذاته. <strong>لذا من المهم جدًا إستشارة الطبيب عندما تطرأ أي تغيرات في صحتك.</strong></p><p dir="RTL">حتى المرضى الذين لا يوجد لديهم جين HLA-B*5701، قد يصابون بتفاعل فرط الحساسية (تفاعل تحسسي خطير)، كما هو موضح في الجزء الذي يحمل عنوان &quot;تفاعلات فرط الحساسية&quot; بهذه النشرة.</p><p dir="RTL"><strong>من المهم جدًا قراءة المعلومات المتعلقة بهذا التفاعل الخطير وفهمها جيدًا.</strong></p><p dir="RTL"><strong>علاوة على الآثار الجانبية الموضحة أدناه لدواء كيـﭭـيكسا،</strong> يمكن أن تتطور بعض الحالات الأخرى أثناء العلاج المركب لفيروس نقص المناعة البشري.</p><p dir="RTL">من المهم قراءة المعلومات الموجودة في الجزء الذي يحمل عنوان &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري&quot;، لاحقًا في هذا القسم.</p><table cellspacing="1" cellpadding="1" border="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>تفاعلات فرط الحساسية</strong></p><p dir="RTL">يحتوي <strong>كيـﭭـيكسا </strong>على <strong>أباكاﭬـير</strong> (وهو مادة فعالة في أدوية مثل <strong>تريزيڤير</strong>، و<strong>ترايوميك</strong> و<strong>زياجين</strong>). يمكن أن يتسبب أباكاﭬـير في حدوث تفاعل تحسسي خطير يعرف بإسم تفاعل فرط الحساسية. يتكرر حدوث تفاعلات فرط الحساسية هذه لدى المرضى الذين يتناولون أدوية تحتوي على أباكاﭬـير.</p><p dir="RTL"><strong>من الذي يتعرض لهذه التفاعلات؟</strong></p><p dir="RTL">يمكن أن يعاني أي شخص يتناول كيـﭭـيكسا من تفاعل فرط الحساسية من أباكاﭬـير، وهو الأمر الذي يمكنه تهديد حياته إذا استمر في تناوله.</p><p dir="RTL">ويزيد احتمال التعرض لهذا التفاعل في حالة وجود جين باسم <strong>HLA-B*5701</strong> (ولكن يظل إحتمال الإصابة قائمًا حتى في حالة عدم وجود هذا الجين). ينبغي فحصك لتحديد وجود هذا الجين قبل وصف دواء كيـﭭـيكسا لك. <strong>إذا كنت على علم بوجود هذا الجين لديك، فأخبر الطبيب قبل تناول كيـﭭـيكسا.</strong></p><p dir="RTL">ظهر تفاعل فرط الحساسية لدى حوالي 3 إلى 4 مرضى من كل 100 مريض تمت معالجتهم بأباكاﭬـير في إحدى التجارب السريرية ولم يكن لديهم جين HLA-B*5701.</p><p dir="RTL"><strong>&lrm;</strong><strong>ما هي الأعراض؟</strong></p><p dir="RTL">أكثر الأعراض شيوعًا هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمى</strong> (إرتفاع درجة الحرارة) و<strong>الطفح الجلدي</strong>.</p><p dir="RTL">الأعراض الشائعة الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الدوار)، القيء (الإستفراغ)، الإسهال، آلام البطن (المعدة)، الإجهاد الشديد.</p><p dir="RTL">تشمل الأعراض الأخرى:</p><p dir="RTL">آلام في المفاصل أو العضلات، أو تورم في العنق، أو ضيق التنفس، أو إلتهاب الحلق، أو السعال، أو شعور متكرر بالصداع،<br />أو إلتهاب في العين (إلتهاب الملتحمة)، أو قرحات في الفم، أو انخفاض في ضغط الدم، أو وخز أو تنميل في اليدين أو القدمين.</p><p dir="RTL"><strong>متى تحدث هذه التفاعلات؟</strong></p><p dir="RTL">يمكن أن تظهر تفاعلات فرط الحساسية في أي وقت خلال فترة العلاج باستخدام كيـﭭـيكسا، ولكن الغالب ظهورها في الأسابيع الستة الأولى من العلاج.</p><p dir="RTL"><strong>اتصل بالطبيب في الحال:</strong></p><p dir="RTL"><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ظهور طفح جلدي أو</strong></p><p dir="RTL"><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت لديك أعراض مجموعتين على الأقل من المجموعات التالية:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الحمى</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - ضيق النفس أو إلتهاب الحلق أو السعال</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الغثيان أو القيء، أو الإسهال أو آلام البطن</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الإجهاد أو الألم الشديد، أو الشعور بالإعياء بشكل عام.</p><p dir="RTL"><strong>قد ينصحك الطبيب بالتوقف عن تناول كيـﭭـيكسا.</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>في حالة التوقف عن تناول كيـﭭـيكسا</strong></p><p dir="RTL">إذا توقفت عن تناول كيـﭭـيكسا بسبب تفاعل فرط الحساسية، <strong>فيجب عليك عدم تناول كيـﭭـيكسا مرة أخرى على الإطلاق، أو أي دواء آخر يحتوي على أباكاﭬـير (مثل تريزيڤير أو ترايوميك أو زياجين).</strong> فإن حدث وتناولت الدواء، فمن الممكن أن يحدث انخفاضًا حادًا خطيرًا في ضغط الدم خلال ساعات قد يؤدي إلى الوفاة.</p><p dir="RTL">في حال التوقف عن تناول كيـﭭـيكسا لأي سبب من الأسباب، خاصة إذا كنت تعتقد أنك تعاني من بعض الأعراض الجانبية أو أنك مُصاب بأي مرض آخر:</p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استئناف تناول الدواء مرة آخرى.</strong> سوف يتحقق الطبيب من علاقة هذه الأعراض بتفاعل فرط الحساسية. إذا رأى الطبيب أن هذه الأعراض قد تكون مرتبطة بتفاعل فرط الحساسية، <strong>فسوف يُطلب منك عدم تناول كيـﭭـيكسا مرة أخرى أو أي دواء آخر يحتوي على أباكاﭬـير (على سبيل المثال: تريزيڤير، أو ترايوميك، أو زياجين).</strong> من المهم الإلتزام بهذه النصيحة.</p><p dir="RTL">أحيانًا تظهر تفاعلات فرط الحساسية لدى المرضى الذين بدءوا في تناول مستحضرات تحتوي على أباكاﭬـير مجددًا، والذين قد سبق أن ظهر لهم عرض واحد فقط من الأعراض المذكورة في بطاقة التنبيه قبل توقفهم عن تناوله.</p><p dir="RTL">من النادر جدًا أن يظهر تفاعل فرط الحساسية لدى المرضى الذين سبق أن تناولوا أدوية تحتوي على أباكاﭬـير ولم تظهر عليهم أي أعراض فرط الحساسية، عندما يبدءون في تناول هذه الأدوية مرة أخرى.</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول كيـﭭـيكسا مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على الرعاية الطبية إن لزم الأمر.&nbsp;&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني من فرط الحساسية لدواء كيـﭭـيكسا، فقم بإعادة جميع أقراص كيـﭭـيكسا غير المستخدمة حتى يتم التخلص منها بشكل آمن.</strong> استشر الطبيب أو الصيدلي لديك بخصوص هذا الأمر.</p><p dir="RTL">تحتوي عبوة كيـﭭـيكسا على <strong>بطاقة تنبيه</strong>، لتذكيرك أنت والطاقم الطبي لديك بتفاعلات فرط الحساسية. <strong>افصل هذه البطاقة واحتفظ بها معك طوال الوقت.</strong></p></td></tr></tbody></table><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">قد تصيب حتى <strong>شخص واحد من كل </strong><strong>10</strong><strong> أشخاص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل فرط الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التوعك <em>(القيء)</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الدوار <em>(الغثيان)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد وفقدان الطاقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (إرتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بعدم الراحة</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>صعوبة في النوم <em>(الأرق)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وعدم راحة في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج أو رشح الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong></p><p dir="RTL">قد تصيب حتى <strong>شخص</strong> <strong>واحد من كل </strong><strong>100</strong> <strong>شخص</strong> وقد تظهر في فحوصات الدم:</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض في عدد خلايا الدم الحمراء <em>(الأنيميا)</em> أو انخفاض في عدد خلايا الدم البيضاء <em>(قلة العدلات)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى إنزيمات الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الخلايا المشاركة في تجلط الدم <em>(نقص الصفائح الدموية)</em>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">قد تصيب حتى <strong>شخص واحد من كل </strong><strong>1000</strong> <strong>شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الكبد، مثل اليرقان، أو تضخم الكبد أو الكبد الدهني، أو الإلتهاب <em>(إلتهاب الكبد الوبائي)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب في البنكرياس <em>(إلتهاب البنكرياس)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق في الأنسجة العضلية.</p><p dir="RTL">الآثار الجانبية النادرة التي قد تظهر في فحوصات الدم هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيم يُعرف باسم <em>الأميلاز</em>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong></p><p dir="RTL">قد تصيب حتى <strong>شخص واحد من كل </strong><strong>10000</strong> <strong>شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل، الشعور بالوخز في الجلد (كوخز بالإبر والدبابيس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بضعف في الأطراف</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>طفح جلدي، قد يسبب بثورًا ويبدو مثل نقاط صغيرة (بقع غامقة مركزية محاطة بمنطقة شاحبة، ذات حلقة سوداء حول الحافة) <em>(حُمامي عديدة الأشكال)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي منتشر مع بثور وتقشّر الجلد، خاصة حول الفم والأنف والعينين والأعضاء التناسلية <em>(متلازمة ستيفنز جونسون)</em>، وشكل أكثر حدة يؤدي إلى تقشر الجلد في أكثر من 30٪ من سطح الجسم <em>(تقشر الأنسجة المتموتة البشروية التسممي)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُماض لاكتيكي (مستويات زائدة من حمض اللاكتيك في الدم)</p><p dir="RTL"><strong>&szlig;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا لاحظت أيًا من هذه الأعراض، فاتصل بالطبيب في الحال.</strong></p><p dir="RTL">الآثار الجانبية النادرة جدًا التي قد تظهر في فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النخاع العظمي في إنتاج خلايا دم حمراء جديدة <em>(عدم تنسج الكريات الحمراء الصرفَة)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong></p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر الطبيب أو الصيدلي</strong> في حال تفاقم أي من الآثار الجانبية أو تسببها في حدوث إزعاج، أو لاحظت أي آثار جانبية غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري</strong></p><p dir="RTL">يمكن أن يؤدي العلاج المركب مثل دواء كيـﭭـيكسا إلى تطور حالات أخرى أثناء علاج فيروس نقص المناعة البشري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض العدوى والإلتهاب</strong></p><p dir="RTL"><strong>احتمال نشاط إصابات سابقة بالعدوى</strong></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى الإيدز (فيروس نقص المناعة البشري) من أجهزة مناعية ضعيفة، ويصبحون أكثر عرضة للإصابة بعدوى خطيرة <em>&nbsp;(عدوى انتهازية)</em>. قد &quot;لا تفصح&quot; هذه العدوى عن نفسها ولا تُظهر أي أعراض، وبالتالي لن يكتشفها الجهاز المناعي الضعيف قبل بدء العلاج. بعد بدء العلاج، يصبح الجهاز المناعي أكثر قوة، ويهاجم العدوى، مما يؤدي إلى ظهور أعراض العدوى أو الإلتهاب. عادة ما تشمل الأعراض <strong>الحمى</strong>، بالإضافة إلى بعض من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">في حالات نادرة، بمجرد أن يصبح الجهاز المناعي أكثر قوة، قد يهاجم أنسجة الجسم السليمة <em>(اضطرابات المناعة الذاتية)</em>. وربما تظهر أعراض اضطرابات المناعة الذاتية بعد عدة أشهر من تناول الدواء لعلاج عدوى فيروس نقص المناعة البشري. قد تشمل الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب (ضربات قلب سريعة أو غير منتظمة) أو الإرتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحركة (التململ والحركة الزائدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين وينتقل لأعلى الجذع في الجسم</p><p dir="RTL"><strong>إذا كنت تعاني أي من أعراض العدوى </strong>والإلتهاب، أو لاحظت أي من الأعراض المذكورة أعلاه:</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك في الحال.</strong> ولا تتناول أي أدوية أخرى لعلاج العدوى دون إستشارة الطبيب.</p><p dir="RTL"><strong>قد تكون لديك مشكلات في العظام</strong></p><p dir="RTL">يظهر لدى بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشري حالة يُطلق عليها <em>النخر العظمي</em>.<br />في هذه الحالة، تموت أجزاء من أنسجة العظام بسبب إنخفاض تدفق الدم إلى العظام. تزداد احتمالية الإصابة بهذه الحالة لدى الأشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون علاجًا مركبًا لفترة طويلة من الوقت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون الأدوية المضادة للإلتهابات التي يُطلق عليها الكورتيكوستيرويد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من ضعف شديد في جهازهم المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من زيادة الوزن.</p><p dir="RTL"><strong>تشمل علامات النخر العظمي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام (وخاصة في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الحركة.</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض: <strong>أخبر طبيبك.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تتناول هذا الدواء بعد انقضاء تاريخ الصلاحية المدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">لا يخزن في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من الأدوية برميها في مياه الصرف أو ضمن المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات سوف تساعد في حماية البيئة.</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL" style="text-align:center"><strong>بطاقة التنبيه</strong></p><p dir="RTL" style="text-align:center"><strong>معلومات العبوة الإلزامية</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>مهم - بطاقة التنبيه</strong></p><p style="text-align:center"><strong>أقراص <em>كيـﭭـيكسا</em> (سلفات أباكاﭬـير/ لاميـﭭـودين)</strong></p><p style="text-align:center"><strong>احتفظ بهذه البطاقة معك طوال الوقت</strong></p></td></tr></tbody></table><p dir="RTL">نظرًا لأن <em>كيـﭭـيكسا </em>يحتوي على أباكاﭬـير، فإن بعض المرضى الذين يتناولون <em>كيـﭭـيكسا </em>قد يظهر لديهم تفاعل فرط حساسية (تفاعل تحسسي خطير) قد <strong>يهدد حياتهم </strong>إذا استمر العلاج بتناول <em>كيـﭭـيكسا</em>. <strong>اتصل بطبيبك على الفور لإستشارته فيما يتعلق بالتوقف عن تناول <em>كيـﭭـيكسا </em>في حالة:</strong></p><p dir="RTL">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهر لديك طفح جلدي أو</p><p dir="RTL">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت لديك أعراض مجموعتين على الأقل من المجموعات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس أو إلتهاب الحلق أو السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء أو الإسهال أو ألم في البطن</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الإجهاد أو الألم الشديد، أو الشعور بالإعياء بشكل عام.</p><p dir="RTL">إذا توقفت عن تناول <em>كيـﭭـيكسا </em>بسبب حدوث هذا التفاعل، <strong>فيجب عليك عدم تناول </strong><em>كيـﭭـيكسا</em> على الإطلاق، أو أي دواء يحتوي على أباكاﭬـير <em>(زياجين، أو</em> <em>تريزيڤير أو ترايوميك)</em> مرة أخرى لأنه <strong>في خلال ساعات </strong>قد تتعرض لانخفاض ضغط الدم بشكل يهدد حياتك أو الوفاة.</p><p dir="RTL"><strong>اللوح الكرتوني</strong></p><p dir="RTL">يجب إدراج النص التالي في إحدى الألواح الكرتونية.</p><p dir="RTL"><strong>تحتوي بطاقة التنبيه المتضمنة على معلومات مهمة حول السلامة</strong></p><p>تحذير! في حالة ظهور أي من الأعراض التي تشير إلى حدوث تفاعلات فرط حساسية، اتصل بطبيبك على الفور.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة في كل قرص كيـﭭـيكسا مغلف بكسوة غشائية هي 600 ملجم أباكاﭬـير (على هيئة سلفات) و300 ملجم لاميـﭭـودين.</p><p dir="RTL"><strong>المكونات الأخرى هي: </strong></p><p dir="RTL"><u>المكونات الأساسية:</u></p><p dir="RTL">ستيرات المغنيسيوم، سليولوز دقيق التبلور، غليكولات النشاء الصودي.</p><p dir="RTL"><u>أغلفة الأقراص: </u></p><p dir="RTL">لون برتقالي YS-1-13065-A يحتوي على:</p><p dir="RTL">هايبروميلوز (E464)، ثنائي أكسيد التيتانيوم (E171)، ماكروجول 400، عديد السوربات 80 &nbsp;(E433)، لاك الألمنيوم الأصفر كلون غروب الشمس (E110).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص كيـﭭـيكسا المغلفة بكسوة غشائية معلم على احدى جانبيها &quot;GS FC2&quot;. أقراص برتقالية اللون على شكل كبسولات وتتوفر في شرائط فقاعية تحتوي على 30 قرصًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>كيـﭭـيكسا</em></strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات ڤيڤ هيلثكير.</p><p dir="RTL">&copy; 2024 جميع الحقوق محفوظة لمجموعة شركات ڤيڤ هيلثكير.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة: </strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>تعبئة:</strong></p><p dir="RTL">جلاكسو ويلكام أس. أيه* أراندا ، إسبانيا&nbsp; &nbsp;</p><p dir="RTL"><strong>مالك التسويق المعتمد</strong><strong>:</strong><strong> </strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية</p><p dir="RTL">*عضو مجموعة شركات جلاكسو سميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: UK_Issue 31 Draft 1
تمت آخر مراجعة لهذه النشرة في 10 يناير 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kivexa 600 mg/300 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 600 mg of abacavir (as sulfate) and 300 mg lamivudine.

Excipient(s) with known effect: sunset yellow FCF (E110) 1.7 mg per tablet

For the full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Orange, film-coated, modified capsule shaped tablets, debossed with GS FC2 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be prescribed by a physician experienced in the management of HIV infection.</p><p><u>Posology</u></p><p><em>Adults, adolescents and children weighing at least 25 kg:</em></p><p>The recommended dose of Kivexa is one tablet once daily.</p><p>&nbsp;</p><p><em>Children Under 25 kg:</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d7407581-add5-4adc-938c-78ed91a0e3bb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Kivexa should not be administered to children who weigh less than 25&nbsp;kg because it is a fixed‑dose tablet that cannot be dose reduced.</p><p>Kivexa is a fixed-dose tablet and should not be prescribed for patients requiring dose adjustments. Separate preparations of abacavir or lamivudine are available in cases where discontinuation or dose adjustment of one of the active substances is indicated. In these cases the physician should refer to the individual product information for these medicinal products.</p><p>&nbsp;</p><p><em>Special Populations</em></p><p><em>Elderly:</em></p><p>No pharmacokinetic data are currently available in patients over 65&nbsp;years of age. Special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters.</p><p>&nbsp;</p><p><em>Renal impairment</em><em>:</em></p><p>Kivexa is not recommended for use in patients with a creatinine clearance &lt;&nbsp;30&nbsp;mL/min (see section 5.2). No dose adjustment is required in patients with mild or moderate renal impairment. However, the lamivudine exposure is significantly increased in patients with a creatinine clearance &lt; 50 mL/min (see section 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment: </em></p><p>Abacavir is primarily metabolised by the liver. No clinical data are available in patients with moderate or severe hepatic impairment, therefore the use of Kivexa is not recommended unless judged necessary. In patients with mild hepatic impairment (Child-Pugh score 5-6) close monitoring is required, including&nbsp; monitoring of abacavir plasma levels if feasible (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>The safety and efficacy of Kivexa in children weighing less than 25 kg has not been established.</p><p>&nbsp;</p><p>Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on posology can be made.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Oral use</p><p>Kivexa can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. See sections 4.4 and 4.8.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The special warnings and precautions relevant to abacavir and lamivudine are included in this section. There are no additional precautions and warnings relevant to Kivexa.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Hypersensitivity reactions </em></strong>(see also section 4.8 )</p><p>Abacavir is associated with a risk for hypersensitivity reactions (HSR) (see section4.8) ) characterised by fever and/or rash with other symptoms indicating multi-organ involvement. HSRs have been observed with abacavir, some of which have been life-threatening, and in rare cases fatal, when not managed appropriately.</p><p>The risk for abacavir HSR to occur is high for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.&nbsp;</p><p>Therefore the following should be adhered to:</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; HLA-B*5701 status must always be documented prior to initiating therapy.</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; Kivexa should never be initiated in patients with a positive HLA-B*5701 status, nor in patients with a negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir-containing regimen. (e.g. Ziagen, Trizivir, Triumeq)</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; <strong>Kivexa must be stopped without delay</strong>, even in the absence of the HLA-B*5701 allele, if an HSR is suspected. Delay in stopping treatment with Kivexa after the onset of hypersensitivity may result in a life-threatening reaction.</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; After stopping treatment with Kivexa for reasons of a suspected HSR, Kivexa<strong> or any other medicinal product containing abacavir </strong>(e.g. Ziagen, Trizivir, Triumeq)<strong> must never be re-initiated</strong>.</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours. This recurrence is usually more severe than on initial presentation, and may include life-threatening hypotension and death.</p><p>!&nbsp;&nbsp;&nbsp;&nbsp; In order to avoid restarting abacavir, patients who have experienced a suspected HSR should be instructed to dispose of their remaining Kivexa tablets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Clinical Description</u></strong><em><u> of abacavir HSR</u></em></p><p>Abacavir HSR has been well characterised through clinical studies and during post marketing follow-up. Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, <strong>although these reactions may occur at any time during therapy.</strong></p><p>Almost all HSR to abacavir include fever and/or rash. Other signs and symptoms that have been observed as part of abacavir HSR are described in detail in section 4.8 (Description of selected adverse reactions), including respiratory and gastrointestinal symptoms. Importantly, such symptoms <strong>may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis.</strong></p><p>The symptoms related to HSR worsen with continued therapy and can be life‑threatening. These symptoms usually resolve upon discontinuation of abacavir.</p><p>Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see Section 4.8 Description of selected adverse reactions).&nbsp; Restarting abacavir in such patients must be done in a setting where medical assistance is readily available.</p></td></tr></tbody></table><p><u>Weight and metabolic parameters</u></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><u>Pancreatitis </u></p><p>Pancreatitis has been reported, but a causal relationship to lamivudine and abacavir is uncertain.</p><p>&nbsp;</p><p><u>Risk of virological failure </u></p><p>- Triple nucleoside therapy: There have been reports of a high rate of virological failure, and of emergence of resistance at an early stage when abacavir and lamivudine were combined with tenofovir disoproxil fumarate as a once daily regimen.</p><p>- The risk of virological failure with Kivexa might be higher than with other therapeutic options (see section 5.1).</p><p>&nbsp;</p><p><u>Liver disease </u></p><p>The safety and efficacy of Kivexa has not been established in patients with significant underlying liver disorders. Kivexa is not recommended in patients with moderate or severe hepatic impairment (see sections 4.2 and 5.2).</p><p>Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.<em> </em></p><p>&nbsp;</p><p><u>Patients co-infected with chronic hepatitis B or C virus</u></p><p>Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.</p><p>If lamivudine is being used concomitantly for the treatment of HIV and hepatitis B virus (HBV), additional information relating to the use of lamivudine in the treatment of hepatitis B infection can be found in the Summary of Product Characteristics for products containing lamivudine that are indicated for the treatment of HBV.</p><p>If Kivexa is discontinued in patients co-infected with HBV, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis (see the Summary of Product Characteristics for products containing lamivudine that are indicated for the treatment of HBV).</p><p>&nbsp;</p><p><u>Mitochondrial dysfunction following exposure in utero</u></p><p>Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues: these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These reactions have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed <em>in utero</em> to nucleotide and nucleotide analogues, who presents with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p>&nbsp;</p><p><u>Immune Reactivation Syndrome</u></p><p>In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and <em>Pneumocystis jirovecii</em> pneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p><em>&nbsp;</em></p><p><u>Osteonecrosis </u></p><p>Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><u>Opportunistic infections </u></p><p>Patients should be advised that Kivexa or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications<strong> </strong>of HIV infection. Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p>&nbsp;</p><p><u>Cardiovascular events</u></p><p>Although the available data from clinical and observational studies with abacavir show inconsistent results, several studies suggest an increased risk of cardiovascular events (notably myocardial infarction) in patients treated with abacavir. Therefore, when prescribing Kivexa, action should be taken to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).</p><p>In addition, alternative treatment options to the abacavir containing regimen should be considered when treating patients with a high cardiovascular risk.</p><p>&nbsp;</p><p><u>Administration in subjects with moderate renal impairment</u></p><p>Patients with a creatinine clearance between 30&nbsp;and 49&nbsp;mL/min receiving Kivexa may experience a 1.6&nbsp;-&nbsp;to 3.3&nbsp;-&nbsp;fold higher lamivudine exposure (AUC) than patients with a creatinine clearance &ge;50&nbsp;mL/min. There are no safety data from randomized, controlled trials comparing Kivexa to the individual components in patients with a creatinine clearance between 30&nbsp;and 49&nbsp;mL/min who received dose-adjusted lamivudine. In the original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were associated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations due to neutropenia or anaemia each occurred in &lt;1% of subjects. Other lamivudine-related adverse events (such as gastro-intestinal and hepatic disorders) may occur.</p><p>Patients with a sustained creatinine clearance between 30&nbsp;and&nbsp;49&nbsp;mL/min who receive Kivexa should be monitored for lamivudine-related adverse events, notably haematologic toxicities. If new or worsening neutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is indicated, which cannot be achieved with Kivexa. Kivexa should be discontinued and the individual components should be used to construct the treatment regimen</p><p>&nbsp;</p><p><u>Drug Interactions:</u></p><p>Kivexa should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine.</p><p>The combination of lamivudine with cladribine is not-recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Kivexa contains the azo colouring agent sunset yellow, which may cause allergic reactions.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kivexa contains abacavir and lamivudine, therefore any interactions identified for these individually are relevant to Kivexa. Clinical studies have shown that there are no clinically significant interactions between abacavir and lamivudine.</p><p>&nbsp;</p><p>Abacavir is metabolised by UDP-glucuronyltransferase (UGT) enzymes and alcohol dehydrogenase; co-administration of inducers or inhibitors of UGT enzymes or with compounds eliminated through alcohol dehydrogenase could alter abacavir exposure. Lamivudine is cleared renally. Active renal secretion of lamivudine<strong><em> </em></strong>in the urine is mediated through organic cation transporters (OCTs); co‑administration of lamivudine with OCT inhibitors may increase lamivudine exposure.</p><p>&nbsp;</p><p>Abacavir and lamivudine are not significantly metabolised by cytochrome P450 enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6) nor do they induce this enzyme system. Lamivudine does not inhibit cytochrome P450 enzymes. Abacavir shows limited potential to inhibit metabolism mediated by CYP3A4 and has been shown in vitro not to inhibit CYP2C9 or CYP 2D6 enzymes. In vitro studies have shown that abacavir has potential to inhibit cytochrome P450 1A1 (CYP1A1). Therefore, there is little potential for interactions with antiretroviral protease inhibitors, non-nucleosides and other medicinal products metabolised by major P450 enzymes.</p><p>Kivexa should not be taken with any other medicinal products containing lamivudine (see section 4.4).</p><p>&nbsp;</p><p>The list below should not be considered exhaustive but is representative of the classes studied.</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Drugs by Therapeutic Area</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Interaction<br />Geometric mean change (%)</strong></p><p><strong>(Possible mechanism)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co‑administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIRETROVIRAL MEDICINAL PRODUCTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Didanosine /Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td rowspan="4" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Didanosine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Zidovudine/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied</p></td></tr><tr><td style="vertical-align:top"><p>Zidovudine/Lamivudine</p><p>Zidovudine 300 mg single dose</p><p>Lamivudine 150 mg single dose&nbsp;</p></td><td style="vertical-align:top"><p>Lamivudine: AUC&nbsp; &laquo;</p><p>Zidovudine : AUC&nbsp; &laquo;</p></td></tr><tr><td style="vertical-align:top"><p>Emtricitabine/Lamivudine</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Due to similarities, Kivexa should not be administered concomitantly with other cytidine analogues, such as emtricitabine.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTI-INFECTIVE PRODUCTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td rowspan="2" style="vertical-align:top"><p>No Kivexa dosage adjustment necessary.</p><p>&nbsp;</p><p>When concomitant administration with co‑trimoxazole is warranted, patients should be monitored clinically.&nbsp; High doses of trimethoprim/ sulfamethoxazole for the treatment of <em>Pneumocystis </em><em>&nbsp;jirovecii </em><em>&nbsp;</em>pneumonia (PCP) and toxoplasmosis have not been studied and should be avoided</p></td></tr><tr><td style="vertical-align:top"><p>Trimethoprim/sulfamethoxazole</p><p>(Co-trimoxazole)/Lamivudine</p><p>(160 mg/800 mg once daily for 5 days/300 mg single dose)</p></td><td style="vertical-align:top"><p>Lamivudine: AUC &shy;40%</p><p>&nbsp;</p><p>Trimethoprim: AUC &laquo;</p><p>Sulfamethoxazole: AUC &laquo;</p><p>&nbsp;</p><p>(organic cation transporter inhibition)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIMYCOBACTERIALS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Potential to slightly decrease abacavir plasma concentrations through UGT induction.</p></td><td rowspan="2" style="vertical-align:top"><p>Insufficient data to recommend dosage adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTICONVULSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Potential to slightly decrease abacavir plasma concentrations through UGT induction.</p></td><td rowspan="2" style="vertical-align:top"><p>Insufficient data to recommend dosage adjustment.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Potential to slightly decrease abacavir plasma concentrations through UGT induction.</p></td><td rowspan="2" style="vertical-align:top"><p>Insufficient data to recommend dosage adjustment.</p><p>&nbsp;</p><p>Monitor phenytoin concentrations.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Drugs by Therapeutic Area</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Interaction<br />Geometric mean change (%)</strong></p><p><strong>(Possible mechanism)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co‑administration</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIHISTAMINES (HISTAMINE H2 RECEPTOR ANTAGONISTS)</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ranitidine/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td rowspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ranitidine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.&nbsp; Ranitidine eliminated only in part by renal organic cation transport system.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cimetidine/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td rowspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cimetidine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.&nbsp; Cimetidine eliminated only in part by renal organic cation transport system.</p></td><td>&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CYTOTOXICS</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cladribine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p><em>In vitro</em> lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine</p></td><td style="vertical-align:top"><p>Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4).</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>OPIOIDS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Methadone/Abacavir</p><p>(40 to 90 mg once daily for 14 days/600 mg single dose, then 600 mg twice daily for 14 days)</p></td><td style="vertical-align:top"><p>Abacavir:&nbsp; AUC &laquo;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; C<sub>max</sub> &macr;35%</p><p>&nbsp;</p><p>Methadone: CL/F &shy;22%</p></td><td rowspan="2" style="vertical-align:top"><p>No Kivexa dosage adjustment necessary.&nbsp;</p><p>&nbsp;</p><p>Methadone dosage adjustment unlikely in majority of patients; occasionally methadone re‑titration may be required.</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Methadone/Lamivudine</p></td><td rowspan="2" style="vertical-align:top"><p>Interaction not studied.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>RETINOIDS</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Retinoid compounds<br />(e.g. isotretinoin)/Abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Possible interaction given common pathway of elimination via alcohol dehydrogenase.</p></td><td style="vertical-align:top"><p>Insufficient data to recommend dosage adjustment.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Retinoid compounds<br />(e.g. isotretinoin)/Lamivudine</p><p>No drug interaction studies</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Drugs by Therapeutic Area</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Interaction<br />Geometric mean change (%)</strong></p><p><strong>(Possible mechanism)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co‑administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MISCELLANEOUS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ethanol/Abacavir</p><p>(0.7 g/kg single dose/600 mg single dose)</p></td><td style="vertical-align:top"><p>Abacavir: AUC &shy;41%</p><p>Ethanol: AUC &laquo;</p><p>&nbsp;</p><p>(Inhibition of alcohol dehydrogenase)</p></td><td rowspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Ethanol/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Sorbitol solution (3.2 g, 10.2&nbsp;g, 13.4&nbsp;g)/ Lamivudine</p></td><td style="vertical-align:top"><p>Single dose lamivudine oral solution 300 mg</p><p>Lamivudine:</p><p>AUC &macr; 14%; 32%; 36%</p><p>Cmax &macr; 28%; 52%, 55%.</p></td><td style="vertical-align:top"><p>When possible, avoid chronic coadministration of Kivexa with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.</p></td></tr><tr><td style="vertical-align:top"><p>Riociguat/Abacavir</p></td><td style="vertical-align:top"><p>Riociguat &shy;</p><p>In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine (600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat AUC(0-&infin;) when compared to historical riociguat AUC(0-&infin;) reported in healthy subjects.</p></td><td style="vertical-align:top"><p>Riociguat dose may need to be reduced. Consult the riociguat prescribing information for dosing recommendations.</p></td></tr></tbody></table><p>Abbreviations: &shy; = Increase; &macr; = decrease; &laquo; = no significant change; AUC = area under the concentration versus time curve; C<sub>max </sub>= maximum observed concentration; CL/F = apparent oral clearance</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as&nbsp;the clinical experience in pregnant women should be taken into account.</p><p>Animal studies with abacavir have shown toxicity to the developing embryo and foetus in rats, but not in rabbits. Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats. (see section 5.3). The active ingredients of Kivexa may inhibit cellular DNA replication and abacavir has been shown to be carcinogenic in animal models (see section 5.3). The clinical relevance of these findings is unknown. Placental transfer of abacavir and lamivudine has been shown to occur in humans.</p><p>In pregnant women treated with abacavir, more than 800 outcomes after first trimester exposure and more than 1000 outcomes after second and third trimester exposure indicate no malformative and foetal/neonatal effect. In pregnant women treated with lamivudine, more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure indicate no malformative and foeto/neonatal effect. There are no data on the use of Kivexa in pregnancy, however the malformative risk is unlikely in humans based on those data.</p><p>For patients co-infected with hepatitis who are being treated with a lamivudine containing medicinal product such as Kivexa and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.<strong><em> </em></strong></p><p><em>Mitochondrial dysfunction</em></p><p>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues (see section 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Abacavir and its metabolites are excreted into the milk of lactating rats. Abacavir is also excreted into human milk.</p><p>Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age. There are no data available on the safety of abacavir and lamivudine when administered to babies less than three months old.</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Studies in animals showed that neither abacavir nor lamivudine had any effect on fertility (see section 5.3). &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed. The clinical status of the patient and the adverse reaction profile of Kivexa should be borne in mind when considering the patient&rsquo;s ability to drive or operate machinery.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The adverse reactions reported for Kivexa were consistent with the known safety profiles of abacavir and lamivudine when given as separate medicinal products. For many of these adverse reactions it is unclear whether they are related to the active substance, the wide range of other medicinal products used in the management of HIV infection, or whether they are a result of the underlying disease process.</p><p>Many of the adverse reactions listed in the table below occur commonly (nausea, vomiting, diarrhoea, fever, lethargy, rash) in patients with abacavir hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity (see section 4.4). Very rarely cases of erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported where abacavir hypersensitivity could not be ruled out. In such cases medicinal products containing abacavir should be permanently discontinued.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions considered at least possibly related to abacavir or lamivudine are listed by body system, organ class and absolute frequency. Frequencies are defined as very common (&gt;&nbsp;1/10), common (&gt;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&gt;&nbsp;1/1000 to &lt;&nbsp;1/100), rare (&gt;&nbsp;1/10,000 to &lt;&nbsp;1/1000), very rare (&lt;&nbsp;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body system</strong></p></td><td style="vertical-align:top"><p><strong>Abacavir</strong></p></td><td style="vertical-align:top"><p><strong>Lamivudine</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic systems disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Uncommon:</em> Neutropenia and anaemia (both occasionally severe), thrombocytopenia</p><p><em>Very rare:</em> Pure red cell aplasia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Common</em>: hypersensitivity</p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common:</em> anorexia</p><p><em>Very rare</em>: lactic acidosis</p></td><td style="vertical-align:top"><p><em>Very rare</em>: lactic acidosis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common</em>: headache</p></td><td style="vertical-align:top"><p><em>Common: </em>Headache, insomnia.</p><p><em>Very rare:</em> Cases of peripheral neuropathy (or paraesthesia) have been reported</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common:</em> Cough, nasal symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common</em>:<em> </em>nausea, vomiting, diarrhoea</p><p><em>Rare</em><em>: </em>pancreatitis has been reported, but a causal relationship to abacavir treatment is uncertain</p></td><td style="vertical-align:top"><p><em>Common: </em>Nausea, vomiting, abdominal pain or cramps, diarrhoea</p><p><em>Rare:</em> Rises in serum amylase. Cases of pancreatitis have been reported</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Uncommon:</em> Transient rises in liver enzymes (AST, ALT),</p><p><em>Rare:</em> Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common</em>: rash (without systemic symptoms)</p><p><em>Very</em><strong> </strong><em>rare</em>: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p><em>Common:</em> Rash, alopecia</p><p><em>Rare: </em>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common: </em>Arthralgia,<strong> </strong>muscle disorders</p><p><em>Rare:</em> Rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common</em>: fever, lethargy, fatigue.</p></td><td style="vertical-align:top"><p><em>Common:</em> fatigue, malaise, fever.</p></td></tr></tbody></table><p>Description of selected adverse reactions</p><p>&nbsp;</p><p><em><u>Abacavir hypersensitivity</u></em></p><p>The signs and symptoms of this HSR are listed below. These have been identified either from clinical studies or post marketing surveillance. Those reported <strong>in at least 10%</strong> of patients with a hypersensitivity reaction are in bold text.</p><p>&nbsp;</p><p>Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Skin</p></td><td style="vertical-align:top"><p><strong>Rash </strong>(usually maculopapular or urticarial)</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal tract</em></p></td><td style="vertical-align:top"><p><strong>Nausea, vomiting, diarrhoea, abdominal pain</strong>, mouth ulceration</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory tract</em></p></td><td style="vertical-align:top"><p><strong>Dyspnoea,</strong> <strong>cough</strong>, sore throat, adult respiratory distress syndrome, respiratory failure</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Miscellaneous</em></p></td><td style="vertical-align:top"><p><strong>Fever, lethargy, malaise</strong>, oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Neurological/Psychiatry</em></p></td><td style="vertical-align:top"><p><strong>Headache</strong>, paraesthesia</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haematological</em></p></td><td style="vertical-align:top"><p>Lymphopenia</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Liver/pancreas</em></p></td><td style="vertical-align:top"><p><strong>Elevated liver function tests, </strong>hepatitis, hepatic failure</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal</em></p></td><td style="vertical-align:top"><p><strong>Myalgia</strong>, rarely myolysis, arthralgia, elevated creatine phosphokinase</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Urology</em></p></td><td style="vertical-align:top"><p>Elevated creatinine, renal failure</p><p>&nbsp;</p></td></tr></tbody></table><p>Symptoms related to this HSR worsen with continued therapy and can be life- threatening and in rare instance, have been fatal.</p><p>&nbsp;</p><p>Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours. This recurrence of the HSR is usually more severe than on initial presentation, and may include life-threatening hypotension and death.<strong> </strong>Similar reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).</p><p>&nbsp;</p><p><em>Metabolic parameters&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4)</p><p><em>Immune reactivation syndrome </em></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p>&nbsp;</p><p><em>Osteonecrosis</em></p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety database to support once daily dosing in paediatric patients comes from the ARROW Trial (COL105677) in which 669 HIV-1 infected paediatric subjects (from 12 months to &le;17 years old). received abacavir and lamivudine either once or twice daily (see section 5.1). Within this population, 104 HIV-1 infected paediatric subjects weighing at least 25 kg received abacavir and lamivudine as Kivexa once daily. No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_8568de39-9340-4df9-bbba-321675ec7993
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp; Email:&nbsp; gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp; Website:&nbsp; https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific symptoms or signs have been identified following acute overdose with abacavir or lamivudine, apart from those listed as undesirable effects.</p><p>&nbsp;</p><p>If overdose occurs the patient should be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infections, combinations. ATC code: J05AR02.</p><p>&nbsp;</p><p><em>Mechanism of action:</em> Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors (NRTIs) and are potent selective inhibitors of HIV-1 and HIV-2 (LAV2 and EHO) replication. Both abacavir and lamivudine are metabolised sequentially by intracellular kinases to the respective 5&#39;-triphosphate (TP) which are the active moieties. Lamivudine‑TP and carbovir-TP (the active triphosphate form of abacavir) are substrates for and competitive inhibitors of HIV reverse transcriptase (RT). However, their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. Abacavir and lamivudine triphosphates show significantly less affinity for host cell DNA polymerases.</p><p>&nbsp;</p><p>&nbsp;No antagonistic effects in vitro were seen with lamivudine and other antiretrovirals (tested agents:didanosine, nevirapine<s> </s>and zidovudine). The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, stavudine, tenofovir<s>&nbsp; </s>or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir. &nbsp;</p><p>&nbsp;</p><p><u>Antiviral Activity in vitro</u></p><p>Both abacavir and lamivudine have been shown to inhibit replication of laboratory strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood lymphocytes (PBLs) and monocyte/macrophages.&nbsp; The concentration of drug necessary to effect viral replication by 50% (EC<sub>50</sub>) or 50% inhibitory concentration (IC<sub>50</sub>) varied according to virus and host cell type.&nbsp;</p><p>The mean EC<sub>50 </sub>for abacavir against laboratory strains of HIV-1IIIB and HIV‑1HXB2 ranged from 1.4 to 5.8&nbsp;mM. The median or mean EC<sub>50</sub> values for lamivudine against laboratory strains of HIV-1 ranged from 0.007 to 2.3&nbsp;mM. The mean EC<sub>50</sub> against laboratory strains of HIV-2 (LAV2 and EHO) ranged from 1.57 to 7.5&nbsp;mM for abacavir and from 0.16 to 0.51&nbsp;mM for lamivudine.</p><p>The EC<sub>50</sub> values of abacavir against HIV-1 Group M subtypes (A-G) ranged from 0.002 to 1.179&nbsp;mM, against Group O from 0.022 to 1.21&nbsp;mM, and against HIV-2 isolates, from 0.024 to 0.49&nbsp;mM. For lamivudine, the EC<sub>50 </sub>values against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170&nbsp;mM, against Group O from 0.030 to 0.160&nbsp;mM and against HIV-2 isolates from 0.002 to 0.120&nbsp;mM in peripheral blood mononuclear cells.</p><p>Baseline HIV-1 samples from therapy-naive subjects with no amino acid substitutions associated with <em>resistance</em> have been evaluated using either the multi-cycle Virco Antivirogram&trade; assay (n=92 from COL40263) or the&nbsp; the single cycle&nbsp; Monogram Biosciences PhenoSense&trade; assay (n=138 from ESS30009). These resulted in median EC<sub>50</sub> values of 0.912&nbsp;mM (range: 0.493 to 5.017&nbsp;mM) and 1.26<em><u> </u></em>&micro;M (range 0.72 to 1.91&nbsp;mM) respectively for abacavir, and median EC<sub>50</sub> values of 0.429&nbsp;mM (range: 0.200 to 2.007&nbsp;mM) and 2.38&nbsp;mM (1.37 to 3.68&nbsp;mM) respectively for lamivudine.</p><p>Phenotypic susceptibility analyses of clinical isolates from antiretroviral-na&iuml;ve patients with&nbsp; HIV-1 Group M non-B subtypes in three studies have each reported that all viruses were fully susceptible to both abacavir and lamivudine; one study of 104 isolates that included subtypes A and A1 (n=26), C&nbsp;(n=1), D (n=66), and the circulating recombinant forms (CRFs)&nbsp; AD (n=9), CD (n=1), and a complex inter-subtype recombinant_cpx (n=1),&nbsp; a second study of 18 isolates including subtype G (n=14) and CRF_AG (n=4) from Nigeria, and a third study of&nbsp; six isolates (n=4 CRF_AG, n=1 A and n=1 undetermined) from Abidjan (C&ocirc;te d&#39;Ivoire).</p><p>HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC<sub>50</sub> fold changes &lt;2.5), and lamivudine (IC<sub>50</sub> fold changes&lt;3.0), except for two CRF02_AG isolates with fold-changes of 2.9 and 3.4 for abacavir.&nbsp; Group O isolates from antiviral na&iuml;ve patients tested for lamivudine activity were highly sensitive.&nbsp;</p><p>The combination of abacavir and lamivudine has demonstrated antiviral activity in cell culture against non-subtype B isolates and HIV-2 isolates with equivalent antiviral activity as for subtype B isolates.</p><p>&nbsp;</p><p><u>Resistance</u></p><p><em>In vivo resistance </em></p><p>Abacavir-resistant isolates of HIV-1 have been selected <em>in-vitro</em> in wild-type strain HIV‑1&nbsp;(HXB2) and are associated with specific genotypic changes in the RT codon region (codons M184V, K65R, L74V and Y115).&nbsp; Selection for the M184V mutation occurred first and resulted in a two-fold increase in IC<sub>50</sub>.&nbsp; Continued passage in increasing concentrations of drug resulted in selection for double RT mutants 65R/184V and 74V/184V or triple RT mutant 74V/115Y/184V.&nbsp; Two mutations conferred a 7- to 8‑fold change in abacavir susceptibility and combinations of three mutations were required to confer more than an 8-fold change in susceptibility.&nbsp; Passage with a zidovudine resistant clinical isolate RTMC also selected for the 184V mutation.</p><p>HIV-1 resistance to lamivudine involves the development of a M184I or, more commonly, M184V amino acid change close to the active site of the viral RT. Passage of HIV-1 (HXB2) in the presence of increasing 3TC concentrations results in high-level (&gt;100 to &gt;500-fold) lamivudine-resistant viruses and the RT M184I or V mutation is rapidly selected.&nbsp; The IC<sub>50</sub> for wild-type HXB2 is 0.24 to 0.6&nbsp;mM, while the IC<sub>50</sub> for M184V containing HXB2 is &gt;100 to 500&nbsp;mM.</p><p>&nbsp;</p><p><u>Antiviral therapy According to Genotypic/Phenotypic Resistance</u></p><p><em>In vivo resistance (Therapy-na&iuml;ve patients) </em></p><p>The M184V or M184I variants arise in HIV-1 infected patients treated with lamivudine-containing antiretroviral therapy.</p><p>Isolates from most patients experiencing virological failure with a regimen containing abacavir in pivotal clinical trials showed either no NRTI-related changes from baseline (45%) or only M184V or M184I selection (45%).&nbsp; The overall selection frequency for M184V or M184I was high (54%), and less common was the selection of L74V (5%), K65R (1%) and Y115F (1%) (see table below).&nbsp; The inclusion of zidovudine in the regimen has been found to reduce the frequency of L74V and K65R selection in the presence of abacavir (with zidovudine: 0/40, without zidovudine: 15/192, 8%).</p><table border="1" cellspacing="0" cellpadding="0" style="width:91%"><tbody><tr><td><p><strong>Therapy</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Abacavir + Combivir<sup>1</sup></strong></p></td><td><p><strong>Abacavir + lamivudine + NNRTI</strong></p></td><td><p><strong>Abacavir + lamivudine + PI (or PI/ritonavir)</strong></p></td><td><p><strong>Total</strong></p></td></tr><tr><td><p><strong>Number of Subjects</strong></p></td><td><p>282</p></td><td><p>1094</p></td><td><p>909</p></td><td><p>2285</p></td></tr><tr><td><p><strong>Number of Virological Failures</strong></p></td><td><p>43</p></td><td><p>90</p></td><td><p>158</p></td><td><p>306</p></td></tr><tr><td><p><strong>Number of On-Therapy&nbsp; Genotypes</strong></p></td><td><p>40 (100%)</p></td><td><p>51 (100%)<sup>2</sup></p></td><td><p>141 (100%)</p></td><td><p>232 (100%)</p></td></tr><tr><td><p><strong>K65R</strong></p></td><td><p>0</p></td><td><p>1 (2%)</p></td><td><p>2 (1%)</p></td><td><p>3 (1%)</p></td></tr><tr><td><p><strong>L74V</strong></p></td><td><p>0</p></td><td><p>9 (18%)</p></td><td><p>3 (2%)</p></td><td><p>12 (5%)</p></td></tr><tr><td><p><strong>Y115F</strong></p></td><td><p>0</p></td><td><p>2 (4%)</p></td><td><p>0</p></td><td><p>2 (1%)</p></td></tr><tr><td><p><strong>M184V/I</strong></p></td><td><p>34 (85%)</p></td><td><p>22 (43%)</p></td><td><p>70 (50%)</p></td><td><p>126 (54%)</p></td></tr><tr><td><p><strong>TAMs<sup>3</sup></strong></p></td><td><p>3 (8%)</p></td><td><p>2 (4%)</p></td><td><p>4 (3%)</p></td><td><p>9 (4%)</p></td></tr></tbody></table><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combivir is a fixed dose combination of lamivudine and zidovudine</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes three non-virological failures and four unconfirmed virological failures.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of subjects with &sup3;1 Thymidine Analogue Mutations (TAMs).</p><p>&nbsp;</p><p>TAMs might be selected when thymidine analogs are associated with abacavir. In a meta-analysis of six clinical trials, TAMs were not selected by regimens containing abacavir without zidovudine (0/127), but were selected by regimens containing abacavir and the thymidine analogue zidovudine (22/86, 26%).</p><p>&nbsp;</p><p><em>In vivo resistance (Therapy experienced patients) </em>&nbsp;</p><p>The M184V or M184I variants arise in HIV-1 infected patients treated with lamivudine-containing antiretroviral therapy and confer high-level resistance to lamivudine.<em> In vitro</em> data tend to suggest that the continuation of lamivudine in anti‑retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness).&nbsp; The clinical relevance of these findings is not established.&nbsp; Indeed, the available clinical data are very limited and preclude any reliable conclusion in the field.&nbsp; In any case, initiation of susceptible NRTIs should always be preferred to maintenance of lamivudine therapy. Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTIs are available.<em>&nbsp;</em></p><p>Clinically significant reduction of susceptibility to abacavir has been demonstrated in clinical isolates of patients with uncontrolled viral replication, who have been pre-treated with and are resistant to other nucleoside inhibitors. In a meta-analysis of five clinical trials where ABC was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/I, 50 (30%) had T215Y/F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.&nbsp; K65R was absent and L74V and Y115F were uncommon (&pound;3%).&nbsp; Logistic regression modelling of the predictive value for genotype (adjusted for baseline plasma HIV-1RNA [vRNA], CD4+ cell count, number and duration of prior antiretroviral therapies) showed that the presence of 3 or more NRTI resistance-associated mutations was associated with reduced response at Week 4 (p=0.015) or 4 or more mutations at median Week 24 (p&pound;0.012). In addition, the 69 insertion complex or the Q151M mutation, usually found in combination with A62V, V75I, F77L and F116Y, cause a high level of resistance to abacavir.</p><table border="1" cellspacing="0" cellpadding="0" style="width:475px"><tbody><tr><td rowspan="2"><p><strong>Baseline Reverse Transcriptase Mutation</strong></p></td><td colspan="3"><p><strong>Week 4</strong></p><p><strong>(n&nbsp;=&nbsp;166)</strong></p></td></tr><tr><td><p><strong>n</strong></p></td><td><p><strong>Median Change vRNA (log<sub>10</sub> c/mL)</strong></p></td><td><p><strong>Percent with &lt;400&nbsp;copies/mL vRNA</strong></p></td></tr><tr><td><p><strong>None</strong></p></td><td><p>15</p></td><td><p>-0.96</p></td><td><p>40%</p></td></tr><tr><td><p><strong>M184V alone </strong></p></td><td><p>75</p></td><td><p>-0.74</p></td><td><p>64%</p></td></tr><tr><td><p><strong>Any one NRTI mutation</strong></p></td><td><p>82</p></td><td><p>-0.72</p></td><td><p>65%</p></td></tr><tr><td><p><strong>Any two NRTI-associated mutations </strong></p></td><td><p>22</p></td><td><p>-0.82</p></td><td><p>32%</p></td></tr><tr><td><p><strong>Any three NRTI-associated mutations</strong></p></td><td><p>19</p></td><td><p>-0.30</p></td><td><p>5%</p></td></tr><tr><td><p><strong>Four or more NRTI-associated mutations</strong></p></td><td><p>28</p></td><td><p>-0.07</p></td><td><p>11%</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Phenotypic resistance and cross-resistance</em>&nbsp;</p><p>Phenotypic resistance to abacavir requires M184V with at least one other abacavir-selected mutation, or M184V with multiple TAMs. Phenotypic cross‑resistance to other NRTIs with M184V or M184I mutation alone is limited. Zidovudine, didanosine, stavudine and tenofovir maintain their antiretroviral activities against such HIV-1 variants. The presence of M184V with K65R does give rise to cross-resistance between abacavir, tenofovir, didanosine and lamivudine, and M184V with L74V gives rise to cross-resistance between abacavir, didanosine and lamivudine. The presence of M184V with Y115F gives rise to cross-resistance between abacavir and lamivudine. Readily available genotypic drug resistance interpretation algorithms and commercially available susceptibility tests have established clinical cut offs for reduced activity for abacavir and lamivudine as separate drug entities that predict susceptibility, partial susceptibility or resistance based upon either direct measurement of susceptibility or by calculation of the HIV-1 resistance phenotype from the viral genotype.&nbsp; Appropriate use of abacavir and lamivudine can be guided using these currently recommended resistance algorithms.</p><p>Cross-resistance between abacavir or lamivudine and antiretrovirals from other classes e.g. PIs or NNRTIs is unlikely.</p><p>&nbsp;</p><p><em><u>Clinical experience</u></em></p><p>Clinical experience with the combination of abacavir and lamivudine as a once daily regimen is mainly based on four studies in treatment-na&iuml;ve subjects, CNA30021, EPZ104057 (HEAT study), ACTG5202, and CNA109586 (ASSERT study) and two studies in treatment-experienced subjects, CAL30001 and ESS30008.</p><p>&nbsp;</p><p><u>Therapy-na&iuml;ve patients</u></p><p>The combination of abacavir and lamivudine as a once daily regimen is supported by a 48 weeks multi‑centre, double-blind, controlled study (CNA30021) of 770 HIV-infected, therapy-na&iuml;ve adults. These were primarily asymptomatic HIV infected patients (CDC stage A). They were randomised to receive either abacavir (ABC) 600&nbsp;mg once daily or 300&nbsp;mg twice daily, in combination with lamivudine 300&nbsp;mg once daily and efavirenz 600&nbsp;mg once daily. The results are summarised by subgroup in the table below:</p><p>&nbsp;</p><p><strong>Efficacy Outcome at Week 48 in CNA30021 by baseline HIV-1 RNA and CD4 Categories (ITTe TLOVR ART na&iuml;ve subjects).</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>ABC QD +3TC+EFV</strong></p><p><strong>(n=</strong><strong>384)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>ABC BID +3TC+EFV</strong></p><p><strong>(</strong><strong>n=</strong><strong>386</strong><strong>)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ITT-E Population</strong></p><p><strong>TLOVR analysis</strong></p></td><td colspan="2" style="vertical-align:top"><p>Proportion with HIV-1 RNA &lt;50 copies/mL</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Subjects</strong></p></td><td style="vertical-align:top"><p>253/384 (66%)</p></td><td style="vertical-align:top"><p>261/386 (68%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline RNA category&nbsp;&nbsp;&nbsp; &lt;100,000 copies/mL</strong></p></td><td style="vertical-align:top"><p>141/217 (65%)</p></td><td style="vertical-align:top"><p>145/217 (67%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline RNA category &gt;=100,000 copies/mL&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>112/167 (67%)</p></td><td style="vertical-align:top"><p>116/169 (69%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4 category &lt;50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>3/ 6 (50%)</p></td><td style="vertical-align:top"><p>4/6 (67%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4 category 50-100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>21/40 (53%)</p></td><td style="vertical-align:top"><p>23/37 (62%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4 category&nbsp; 101-200&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>57/ 85 (67%)</p></td><td style="vertical-align:top"><p>43/67 (64%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4 category&nbsp; 201-350&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>101/143 (71%)</p></td><td style="vertical-align:top"><p>114/170 (67%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4 category &gt;350&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>71/109 (65%)</p></td><td style="vertical-align:top"><p>76/105 (72%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;1 log reduction in HIV RNA&nbsp; or &lt;50 cp/mL</strong></p><p><strong>All Patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>372/384 (97%)</p></td><td style="vertical-align:top"><p>373/386 (97%)</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Similar clinical success (point estimate for treatment difference: -1.7, 95% CI &ndash;8.4, 4.9) was observed for both regimens. From these results, it can be concluded with 95% confidence that the true difference is no greater than 8.4% in favour of the twice daily regimen. This potential difference is sufficiently small to draw an overall conclusion of non-inferiority of abacavir once daily over abacavir twice daily.</p><p>There was a low, similar overall incidence of virologic failure (viral load &gt;&nbsp;50 copies/mL) in both the once and twice daily treatment groups (10% and 8% respectively). In the small sample size for genotypic analysis, there was a trend toward a higher rate of NRTI-associated mutations in the once daily versus the twice daily abacavir regimens. No firm conclusion could be drawn due to the limited data derived from this study.<strong>&nbsp;</strong></p><p>There are conflicting data in some comparative studies with Kivexa <em>i.e. HEAT, ACTG5202 and ASSERT</em>:</p><p>EPZ104057 (HEAT study) was a randomised, double-blind, placebo-matched, 96 week, multi-centre study with the primary objective of evaluating the relative efficacy of abacavir/lamivudine (ABC/3TC, 600mg/300mg) and tenofovir /emtricitabine (TDF/FTC, 300mg/200mg), each given once-daily in combination with lopinavir/ritonavir (LPV/r, 800mg/200mg) in HIV-infected, therapy-naive adults.&nbsp; The primary efficacy analysis was performed at week 48 with study continuation to week 96 and demonstrated non-inferiority.&nbsp; The results are summarised below:</p><p>&nbsp;</p><p><strong>Virologic Response Based on Plasma HIV-1 RNA &lt;&nbsp;50 copies/mL </strong></p><p><strong>ITT-Exposed Population M=F switch included</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Virologic Response</strong></p></td><td colspan="2"><p><strong>ABC/3TC +LPV/r </strong></p><p><strong>(N = 343)</strong></p></td><td colspan="2"><p><strong>TDF/FTC + LPV/r</strong></p><p><strong>(N = 345)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 48</strong></p></td><td style="vertical-align:top"><p><strong>Week 96</strong></p></td><td style="vertical-align:top"><p><strong>Week 48</strong></p></td><td style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response (stratified by baseline HIV-1 RNA)</strong></p></td><td style="vertical-align:top"><p>231/343 (68%)</p></td><td style="vertical-align:top"><p>205/343 (60%)</p></td><td style="vertical-align:top"><p>232/345 (67%)</p></td><td style="vertical-align:top"><p>200/345 (58%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response by Baseline HIV-1 RNA &lt;100,000 c/mL</strong></p></td><td style="vertical-align:top"><p>134/188 (71%)</p></td><td style="vertical-align:top"><p>118/188 (63%)</p></td><td style="vertical-align:top"><p>141/205 (69%)</p></td><td style="vertical-align:top"><p>119/205 (58%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response by Baseline HIV-1 RNA </strong><strong>&sup3;</strong><strong>100,000 c/mL</strong></p></td><td style="vertical-align:top"><p>97/155 (63%)</p></td><td style="vertical-align:top"><p>87/155 (56%)</p></td><td style="vertical-align:top"><p>91/140 (65%)</p></td><td style="vertical-align:top"><p>81/140 (58%)</p></td></tr></tbody></table><p>&nbsp;</p><p>A similar virologic response was observed for both regimens (point estimate for treatment difference at week 48: 0.39%, 95% CI<strong><em>:</em></strong> -6.63, 7.40).</p><p>ACTG 5202 study was a, multi-centre, comparative, randomised study of double-blind abacavir/lamivudine or emtricitabine/tenofovir in combination with open-label efavirenz or atazanavir/ritonavir in treatment-na&iuml;ve HIV-1 infected patients. Patients were stratified at screening based on plasma HIV-1 RNA levels &lt; 100,000 and &ge; 100,000 copies/mL.</p><p>An interim analysis from ACTG 5202 revealed that abacavir/lamivudine was associated with a statistically significantly higher risk of virological failure as compared to emtricitabine/tenofovir (defined as viral load &gt;1000 copies/mL at or after 16 weeks and before 24 weeks or HIV-RNA level &gt;200 copies/mL at or after 24 weeks) in subjects with a screening viral load &ge;100,000 copies/mL (estimated hazard ratio: 2.33, 95% CI: 1.46, 3.72, p=0.0003). The Data Safety Monitoring Board (DSMB) recommended that consideration be given to change in the therapeutic management of all subjects in the high viral load stratum due to the efficacy differences observed. The subjects in the low viral load stratum remained blinded and on-study.</p><p>Analysis of the data from subjects in the low viral load stratum showed no demonstrable difference between the nucleoside backbones in the proportion of patients free of virological failure at week 96. The results are presented below:</p><p>- 88.3% with ABC/3TC vs 90.3% with TDF/FTC when taken with atazanavir/ritonavir as third drug, treatment difference -2.0% (95% CI -7.5%, 3.4%),</p><p>- 87.4% with ABC/3TC vs 89.2% with TDF/FTC, when taken with efavirenz as third drug, treatment difference -1.8% (95% CI -7.5%, 3.9%).</p><p>CNA109586 (ASSERT study), a multi-centre, open label, randomised study of abacavir/lamivudine (ABC/3TC, 600mg/300mg) and tenofovir/emtricitabine (TDF/FTC, 300mg/200mg), each given once daily with efavirenz (EFV, 600mg) in ART na&iuml;ve, HLA-B*5701 negative, HIV-1 infected adults.The virologic results are summarised in the table below:</p><p>&nbsp;</p><p><strong>Virologic Response at Week 48 ITT-Exposed Population &lt; 50 copies/mL TLOVR</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>ABC/3TC + EFV</strong></p><p><strong>(N =192)</strong></p></td><td><p><strong>TDF/FTC + EFV</strong></p><p><strong>(N =193)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response</strong></p></td><td style="vertical-align:top"><p>114/192</p><p>(59%)</p></td><td style="vertical-align:top"><p>137/193</p><p>(71%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response by Baseline HIV-1 RNA &lt;100,000 c/mL</strong></p></td><td style="vertical-align:top"><p>61/95</p><p>(64%)</p></td><td style="vertical-align:top"><p>62/83</p><p>(75%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response by Baseline HIV-1 RNA </strong><strong>&sup3;</strong><strong>100,000 c/mL</strong></p></td><td style="vertical-align:top"><p>53/97</p><p>(55%)</p></td><td style="vertical-align:top"><p>75/110</p><p>(68%)</p></td></tr></tbody></table><p>&nbsp;</p><p>At week 48, a lower rate of virologic response was observed for ABC/3TC compared to TDF/FTC (point estimate for the treatment difference: 11.6%, 95% CI<strong><em>:</em></strong> 2.2, 21.1).</p><p>&nbsp;</p><p><u>Therapy-experienced patients</u></p><p>Data from two studies, CAL30001 and ESS30008 demonstrated that Kivexa once daily has similar virological efficacy to abacavir 300 mg twice daily plus lamivudine 300 mg once daily or 150 mg twice daily in therapy-experienced patients.</p><p>In study CAL30001, 182 treatment-experienced patients with virologic failure were randomised and received treatment with either Kivexa once daily or abacavir 300&nbsp;mg twice daily plus lamivudine 300&nbsp;mg once daily, both in combination with tenofovir and a PI or an NNRTI for 48 weeks. Similar reductions in HIV-1 RNA as measured by average area under the curve minus baseline were observed, indicating that the Kivexa group was non-inferior to the abacavir plus lamivudine twice daily group (AAUCMB, -1.65 log<sub>10</sub> copies/mL versus -1.83 log<sub>10</sub> copies/mL respectively, 95% CI -0.13, 0.38). Proportions with HIV-1 RNA &lt;&nbsp;50 copies/mL (50% versus 47%) and &lt;&nbsp;400 copies/mL (54% versus 57%) at week 48 were also similar in each group (ITT population). However, as there were only moderately experienced patients included in this study with an imbalance in baseline viral load between the arms, these results should be interpreted with caution.</p><p>In study ESS30008, 260 patients with virologic suppression on a first line therapy regimen containing abacavir 300&nbsp;mg plus lamivudine 150&nbsp;mg, both given twice daily and a PI or NNRTI, were randomised to continue this regimen or switch to Kivexa plus a PI or NNRTI for 48 weeks. Results at 48 weeks indicated that the Kivexa group was associated with a similar virologic outcome (non-inferior) compared to the abacavir plus lamivudine group, based on proportions of subjects with HIV-1 RNA &lt;&nbsp;50 copies/mL (90% and 85% respectively, 95% CI&nbsp; -2.7, 13.5).</p><p>A genotypic sensitivity score (GSS) has not been established by the MAH for the abacavir/lamivudine combination.&nbsp; The proportion of treatment‑experienced patients in the CAL30001 study with HIV-RNA &lt;50&nbsp;copies/mL at Week 48 by genotypic sensitivity score in optimized background therapy (OBT) are tabulated. The impact of major IAS-USA defined mutations to abacavir or lamivudine and multi-NRTI resistance associated mutations to the number of baseline mutations on response was also evaluated. The GSS was obtained from the Monogram reports with susceptible virus ascribed the values &lsquo;1-4&rsquo; based upon the numbers of drugs in the regimen and with virus with reduced susceptibility ascribed the value &lsquo;0&rsquo;.&nbsp; Genotypic sensitivity scores were not obtained for all patients at baseline.&nbsp; Similar proportions of patients in the once-daily and twice-daily abacavir arms of CAL30001 had GSS scores of &lt;2 or &sup3;2 and successfully suppressed to &lt;50&nbsp;copies/mL by Week 48.</p><p>&nbsp;</p><p><strong>Proportion of Patients in CAL30001 with &lt;50&nbsp;copies/mL at Week 48 by Genotypic Sensitivity Score in OBT and Number of Baseline Mutations</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>ABC/3TC FDC QD</strong></p><p><strong>(n=94)</strong></p><p>&nbsp;</p><p>Number of Baseline Mutations<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>ABC BID +3TC QD</strong></p><p><strong>(n=88)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotypic SS in OBT</strong></p></td><td style="vertical-align:top"><p>All</p></td><td style="vertical-align:top"><p>0-1</p></td><td style="vertical-align:top"><p>2-5</p></td><td style="vertical-align:top"><p>6+</p></td><td style="vertical-align:top"><p>All</p></td></tr><tr><td style="vertical-align:top"><p><strong>&pound;</strong><strong>2</strong></p></td><td style="vertical-align:top"><p>10/24 (42%)</p></td><td style="vertical-align:top"><p>3/24 (13%)</p></td><td style="vertical-align:top"><p>7/24 (29%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12/26 (46%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;2</strong></p></td><td style="vertical-align:top"><p>29/56 (52%)</p></td><td style="vertical-align:top"><p>21/56 (38%)</p></td><td style="vertical-align:top"><p>8/56 (14%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>27/56 (48%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unknown</strong></p></td><td style="vertical-align:top"><p>8/14 (57%)</p></td><td style="vertical-align:top"><p>6/14 (43%)</p></td><td style="vertical-align:top"><p>2/14 (14%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2/6 (33%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>All</strong></p></td><td style="vertical-align:top"><p>47/94 (50%)</p></td><td style="vertical-align:top"><p>30/94 (32%)</p></td><td style="vertical-align:top"><p>17/94 (18%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>41/88 (47%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1 </sup>Major IAS-USA defined mutations to Abacavir or Lamivudine and multi-NRTI resistance associated mutations</p><p>&nbsp;</p></td></tr></tbody></table><p>For the CNA109586 (ASSERT) and CNA30021 studies in treatment-na&iuml;ve patients, genotype data was obtained for only a subset of patients at screening or at baseline, as well as for those patients who met virologic failure criteria.&nbsp; The partial patient subset of data available for CNA30021 is tabulated below, but must be interpreted with caution.&nbsp; Drug susceptibility scores were assigned for each patient&rsquo;s viral genotype utilising the ANRS 2009 HIV-1 genotypic drug resistance algorithm.&nbsp; Each susceptible drug in the regimen received a score of 1 and drugs for which the ANRS algorithm predicts resistance were ascribed the value &lsquo;0&rsquo;.</p><p>&nbsp;</p><p><strong>Proportion of Patients in CNA30021with &lt;50&nbsp;cps/mL at Week 48 by Genotypic Sensitivity Score in OBT and Number of Baseline Mutations</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>ABC QD + 3TC QD + EFV QD</strong></p><p><strong>(N=384)</strong></p><p>Number of Baseline Mutations<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>ABC BID+ 3TC QD + EFV QD</strong></p><p><strong>(N=386)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotypic SS in OBT</strong></p></td><td style="vertical-align:top"><p>All</p></td><td style="vertical-align:top"><p>0-1</p></td><td style="vertical-align:top"><p>2-5</p></td><td style="vertical-align:top"><p>6+</p></td><td style="vertical-align:top"><p>All</p></td></tr><tr><td style="vertical-align:top"><p><strong>&pound;</strong><strong>2</strong></p></td><td style="vertical-align:top"><p>2/6 (33%)</p></td><td style="vertical-align:top"><p>2/6 (33%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3/6 (50%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;2</strong></p></td><td style="vertical-align:top"><p>58/119 (49%)</p></td><td style="vertical-align:top"><p>57/119 (48%)</p></td><td style="vertical-align:top"><p>1/119 (&lt;1%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>57/114 (50%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>All</strong></p></td><td style="vertical-align:top"><p>60/125 (48%)</p></td><td style="vertical-align:top"><p>59/125 (47%)</p></td><td style="vertical-align:top"><p>1/125 (&lt;1%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>60/120 (50%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><u><sup>1 </sup></u>Major IAS-USA (Dec 2009) defined mutations for Abacavir or Lamivudine</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Paediatric population</em></p><p>A comparison of a regimen including once daily versus twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). After 36 weeks on a regimen including twice daily abacavir and lamivudine, 669 eligible subjects were randomised to either continue twice daily dosing or switch to once daily abacavir and lamivudine for at least an additional 96 weeks. Within this population, 104 patients, weighing at least 25 kg, received 600 mg abacavir and 300 mg lamivudine as Kivexa once daily, with a median duration of exposure of 596 days.</p><p>Among the 669 subjects randomized in this study (from 12 months to &le;17 years old), the abacavir/lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of &lt;80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (&lt;200c/mL, &lt;400c/mL, &lt;1000c/mL), which all fell well within this non-inferiority margin. Subgroup analyses testing for heterogeneity of once versus twice daily demonstrated no significant effect of sex, age, or viral load at randomisation. Conclusions supported non-inferiority regardless of analysis method.</p><p>Among the 104 patients who received Kivexa, including the ones who were between 40 kg and 25 kg, the viral suppression was similar</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The fixed-dose combination tablet of abacavir/lamivudine (FDC) has been shown to be bioequivalent to lamivudine and abacavir administered separately. This was demonstrated in a single dose, 3-way crossover bioequivalence study of FDC (fasted) versus 2 x 300&nbsp;mg abacavir tablets plus 2 x 150&nbsp;mg lamivudine tablets (fasted) versus FDC administered with a high fat meal, in healthy volunteers (n&nbsp;=&nbsp;30). In the fasted state there was no significant difference in the extent of absorption, as measured by the area under the plasma concentration‑time curve (AUC) and maximal peak concentration (C<sub>max</sub>), of each component. There was also no clinically significant food effect observed between administration of FDC in the fasted or fed state. These results indicate that FDC can be taken with or without food. The pharmacokinetic properties of lamivudine and abacavir are described below.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Abacavir and lamivudine are rapidly and well absorbed from the gastro-intestinal tract following oral administration. The absolute bioavailability of oral abacavir and lamivudine in adults is about 83% and 80-85% respectively. The mean time to maximal serum concentrations (t<sub>max</sub>) is about 1.5&nbsp;hours and 1.0&nbsp;hour for abacavir and lamivudine, respectively. Following a single dose of 600&nbsp;mg of abacavir, the mean (CV) C<sub>max</sub> is 4.26&nbsp;&micro;g/mL (28%) and the mean (CV) AUC<sub>&yen;</sub><sub> </sub>is 11.95&nbsp;&micro;g.h/mL (21%). Following multiple-dose oral administration of lamivudine 300&nbsp;mg once daily for seven days, the mean (CV) steady-state C<sub>max</sub> is 2.04&nbsp;&micro;g/mL (26%) and the mean (CV) AUC<sub>24</sub> is 8.87&nbsp;&micro;g.h/mL (21%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Intravenous studies with abacavir and lamivudine showed that the mean apparent volume of distribution is 0.8 and 1.3&nbsp;l/kg respectively. Plasma protein binding studies <em>in vitro</em> indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding <em>in vitro</em> (&lt;&nbsp;36%). This indicates a low likelihood for interactions with other medicinal products through plasma protein binding displacement.</p><p>Data show that abacavir and lamivudine penetrate the central nervous system (CNS) and reach the cerebrospinal fluid (CSF). Studies with abacavir demonstrate a CSF to plasma AUC ratio of between 30 to 44%. The observed values of the peak concentrations are 9 fold greater than the IC<sub>50</sub> of abacavir of 0.08&nbsp;&micro;g/mL or 0.26&nbsp;&micro;M when abacavir is given at 600&nbsp;mg twice daily.<strong> </strong>The mean ratio of CSF/serum lamivudine concentrations 2-4&nbsp;hours after oral administration was approximately 12%. The true extent of CNS penetration of lamivudine and its relationship with any clinical efficacy is unknown.</p><p><strong>&nbsp;</strong></p><p><u>Biotransformation</u></p><p>Abacavir is primarily metabolised by the liver with approximately 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5&rsquo;-carboxylic acid and 5&rsquo;-glucuronide which account for about 66% of the administered dose. These metabolites are excreted in the urine.</p><p>Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared by renal excretion of unchanged lamivudine. The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean half-life of abacavir is about 1.5&nbsp;hours. Following multiple oral doses of abacavir 300&nbsp;mg twice a day there is no significant accumulation of abacavir. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83% of the administered abacavir dose in the urine. The remainder is eliminated in the faeces.</p><p>The observed lamivudine half-life of elimination is 18 to19&nbsp;hours. The mean systemic clearance of lamivudine is approximately 0.32&nbsp;l/h/kg, predominantly by renal clearance (&gt;&nbsp;70%) via the organic cationic transport system. Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Kivexa is not recommended for use in patients with a creatinine clearance &lt;&nbsp;30&nbsp;mL/min as necessary dose adjustment cannot be made (see section 4.2).</p><p>&nbsp;</p><p><u>Intracellular pharmacokinetics</u></p><p>In a study of 20 HIV-infected patients receiving abacavir 300&nbsp;mg twice daily, with only one 300&nbsp;mg dose taken prior to the 24&nbsp;hour sampling period, the geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6&nbsp;hours, compared to the geometric mean abacavir plasma half-life in this study of 2.6&nbsp;hours. In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600&nbsp;mg once daily regimen (AUC<sub>24,ss </sub>&nbsp;+&nbsp;32%, C<sub>max24,ss</sub> +&nbsp;99% and C<sub>trough</sub> +&nbsp;18%) compared to the 300&nbsp;mg twice daily regimen. For patients receiving lamivudine 300&nbsp;mg once daily, the terminal intracellular half-life of lamivudine-TP and the plasma lamivudine half-life were similar (16-19 hours and 18-19 hours respectively). In a crossover study in 60 healthy volunteers, intracellular lamivudine-TP pharmacokinetic parameters were similar (AUC<sub>24,ss<em> </em></sub>and C<sub>max24,ss</sub>) or lower (C<sub>trough</sub> &ndash;&nbsp;24%) for the lamivudine 300&nbsp;mg once daily regimen compared to the lamivudine 150&nbsp;mg twice daily regimen. Overall, these data support the use of lamivudine 300&nbsp;mg and abacavir 600&nbsp;mg once daily for the treatment of HIV-infected patients. Additionally, the efficacy and safety of this combination given once daily has been demonstrated in a pivotal clinical study (CNA30021- See Clinical experience).</p><p>&nbsp;</p><p><u>Special&nbsp; patient populations</u></p><p><em>Hepatic impairment </em></p><p>Pharmacokinetic data has been obtained for abacavir and lamivudine separately.</p><p>Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600&nbsp;mg dose; the median (range) AUC value was 24.1 (10.4 to 54.8) &micro;g.h/mL.The results showed that there was a mean (90%CI) increase of 1.89 fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life. No definitive recommendation on dose reduction is possible in patients with mild hepatic impairment due to substantial variability of abacavir exposure.</p><p>Data obtained in patients with moderate to severe hepatic impairment show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.</p><p>Based on data obtained for abacavir, Kivexa is not recommended in patients with moderate or severe hepatic impairment.</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>Pharmacokinetic data have been obtained for lamivudine and abacavir alone. Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function. Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance. Kivexa is not recommended for use in patients with a creatinine clearance &lt;&nbsp;30&nbsp;mL/min as necessary dose adjustment cannot be made.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Elderly</em></p><p>No pharmacokinetic data are available in patients over 65 years of age.</p><p>&nbsp;</p><p><em>Children</em></p><p>Abacavir is rapidly and well absorbed from oral formulations when administered to children.&nbsp; Paediatric pharmacokinetic studies have demonstrated that once daily dosing provides equivalent AUC<sub>24</sub> to twice daily dosing of the same total daily dose for both oral solution and tablet formulations.</p><p>The absolute bioavailability of lamivudine (approximately 58 to 66%) was lower and more variable in paediatric patients under 12 years of age.&nbsp; However, paediatric pharmacokinetic studies with tablet formulations have demonstrated that once daily dosing provides equivalent AUC<sub>24 </sub>to twice daily dosing of the same total daily dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>With the exception of a negative <em>in vivo</em> rat micronucleus test, there are no data available on the effects of the combination of abacavir and lamivudine in animals.<em><u> </u></em></p><p>&nbsp;</p><p><u>Mutagenicity and carcinogenicity</u></p><p>Neither abacavir nor lamivudine were mutagenic in bacterial tests, but consistent with other nucleoside analogues, they inhibit cellular DNA replication in <em>in vitro</em> mammalian tests such as the mouse lymphoma assay. The results of an <em>in vivo</em> rat micronucleus test with abacavir and lamivudine in combination were negative.</p><p>Lamivudine has not shown any genotoxic activity in the <em>in vivo</em> studies at doses that gave plasma concentrations up to 40-50&nbsp;times higher than clinical plasma concentrations. Abacavir has a weak potential to cause chromosomal damage both <em>in vitro</em> and <em>in vivo</em> at high tested concentrations.</p><p>The carcinogenic potential of a combination of abacavir and lamivudine has not been tested. In long‑term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential. Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and in the liver, urinary bladder, lymph nodes and the subcutis of females.</p><p>The majority of these tumours occurred at the highest abacavir dose of 330&nbsp;mg/kg/day in mice and 600&nbsp;mg/kg/day in rats. The exception was the preputial gland tumour which occurred at a dose of 110&nbsp;mg/kg in mice. The systemic exposure at the no effect level in mice and rats was equivalent to 3 and 7 times the human systemic exposure during therapy. While the clinical relevance of these findings is unknown, these data suggest that a carcinogenic risk to humans is outweighed by the potential clinical benefit.</p><p>&nbsp;</p><p><u>Repeat-dose toxicity</u></p><p>In toxicology studies abacavir was shown to increase liver weights in rats and monkeys. The clinical relevance of this is unknown. There is no evidence from clinical studies that abacavir is hepatotoxic. Additionally, autoinduction of abacavir metabolism or induction of the metabolism of other medicinal products hepatically metabolised has not been observed in man.</p><p>Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>In reproductive toxicity studies in animals, lamivudine and abacavir were shown to cross the placenta.</p><p>Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A similar effect was not seen in rats even at very high systemic exposure.</p><p>Abacavir demonstrated toxicity to the developing embryo and foetus in rats, but not in rabbits. These findings included decreased foetal body weight, foetal oedema, and an increase in skeletal variations/malformations, early intra-uterine deaths and still births. No conclusion can be drawn with regard to the teratogenic potential of abacavir because of this embryo-foetal toxicity.</p><p>A fertility study in rats has shown that abacavir and lamivudine had no effect on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet Core</u></p><p>Magnesium stearate</p><p>Microcrystalline cellulose</p><p>Sodium starch glycollate</p><p><u>Tablet Coating</u></p><p>Opadry Orange YS-1-13065-A containing:</p><p>Hypromellose (E464))</p><p>Titanium dioxide (E171)</p><p>Polyethylene glycol 400</p><p>Polysorbate 80 (E433)</p><p>Sunset yellow aluminium lake (E110).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 tablets in opaque white (PVC/PVDCAluminium/Paper) child-resistant<strong><em> </em></strong>blister packs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p><strong><em>Kivexa</em></strong> is a trademark owned by or licensed to the ViiV Healthcare group of companies.</p><p>&copy; 2024 ViiV Healthcare group of companies. All rights reserved</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland

Packed by:
Glaxo Wellcome S.A.*, Aranda, Spain

Marketing Authorisation Holder: 
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia
*member of GSK group of companies 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of Revision of the Text: 10 January 2024 
Version Number: UK_Issue 42 Draft 1
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>